

Contracts Listings - Grants							
Reporting Period - Financial Years 2011-12 to 2019-20							
Reporting Period	Grant Recipient / Supplier	Description	Commencement Date	Completion Date	Confidentiality Provision Y/N	Confidentiality Provision: Reason	Contract Value (GST incl)
2015-16	Aboriginal Health and Medical Research Council NSW	Supporting People with Cancer - Develop locally led Aboriginal cancer networks to support local communities affected by cancer.	30/06/2015	30/06/2018	N		\$132,000.00
2016-17	Aboriginal Health and Medical Research Council NSW	Supporting People with Cancer - Develop locally led Aboriginal cancer networks to support local communities affected by cancer.	30/06/2015	30/06/2018	N	NA	\$132,000.00
2014-15	Aboriginal Health and Medical Research Council NSW	Supporting People with Cancer - Develop locally led Aboriginal cancer networks to support local communities affected by cancer.	30/06/2015	30/06/2018	N		\$132,000.00
2011-12	ACT Health	Cancer Services Networks National Demonstration Program in ACT	29/06/2010	30/06/2012	N		\$529,762.00
2011-12	Adelaide Research and Innovation Pty Ltd	Research into the factors that influence the outcome of cancer related multidisciplinary teams	25/05/2010	30/06/2012	N		\$606,310.11
2012-13	Amanda McBride	Senior Clinical Advice	2/08/2011	1/08/2013	N		\$197,340.00
2011-12	Amanda McBride	Senior Clinical Advisor reporting to General Manager (Clinical Practice and Service Delivery)	2/08/2011	1/08/2013	N		\$199,237.50
2013-14	Anti-Cancer Council Victoria	Development and evaluation of business rules to support the national collection fo cancer stage data from existing cancer registry data sources.	30/06/2014	30/06/2015	N	N	\$284,000.00
2011-12	Australia and New Zealand Breast Cancer Trials Group	Support for Cancer Clinical Trials	25/06/2010	30/06/2013	N		\$1,541,639.00
2019-20	Australia and New Zealand Breast Cancer Trials Group	Capacity building support to the Breast Cancer Trials (BCT) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,644,039
2013-14	AOT Group Pty Ltd	Provide accommodation booking system to Cancer Australia as part of the Phase 2 implementation.	1/07/2013	30/06/2015	N	N	\$132,000.00
2012-13	AOT Group Pty Ltd	Provide accommodation booking system to Cancer Australia as part of the Phase 2 implementation.	1/07/2013	30/06/2015	N		\$132,000.00
2012-13	Aurion Corporation Pty Ltd	Human Resource/Payroll Management System	1/07/2012	30/06/2013	N		\$152,616.40
2011-12	Aurion Corporation Pty Ltd	Human Resource/Payroll Management System	1/07/2012	30/06/2013	N		\$152,616.40
2013-14	Austin Health	Procurement of evaluation data: Shared follow-up care for women with early breast cancer 2013-2015	26/06/2012	15/09/2015	N	N	\$140,000.00
2018-19	Austin Health	2019 Supporting People with Cancer Round 11	26/03/2019	30/06/2020	N	N	\$132,000.00
2019-20	Austin Health	Supporting People with Cancer Grant Initiative: An investigation of perspectives of people with cancer, carers and health professionals and development of practice resources.	26/03/2019	30/08/2020	N	N	\$132,000
2017-18	Austin Health/Olivia Newton-John Cancer Centre	Supporting people with cancer Grant initiative	5/04/2018	30/03/2021	N	N	\$130,705.30
2019-20	Austin Health/Olivia Newton-John Cancer Centre	Supporting people with cancer Grant initiative:Optimising the engagement of Culturally and Linguistically Diverse cancer patients and their families with supportive care designed to improve wellness.	05/04/2018	30/03/2021	N	N	\$130,705
2017-18	Australasian Gastro-Intestinal Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/06/2018	1/09/2021	N	N	\$1,500,000.00
2017-18	Australasian Gastro-Intestinal Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	25/06/2018	31/08/2018	N	N	\$2,300,000.00
2015-16	Australasian Gastro-Intestinal Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2016	N		\$1,380,000.00
2016-17	Australasian Gastro-Intestinal Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2018	N	NA	\$2,300,000.00
2014-15	Australasian Gastro-Intestinal Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,380,000.00
2013-14	Australasian Gastro-Intestinal Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N	N	\$1,380,000.00
2012-13	Australasian Gastro-Intestinal Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,380,000.00
2017-18	Australasian Leukaemia and Lymphoma Group	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	25/06/2018	31/08/2018	N	N	\$2,530,000.00
2015-16	Australasian Leukaemia and Lymphoma Group	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2016	N		\$1,518,000.00
2016-17	Australasian Leukaemia and Lymphoma Group	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2018	N	NA	\$2,530,000.00
2014-15	Australasian Leukaemia and Lymphoma Group	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,518,000.00
2013-14	Australasian Leukaemia and Lymphoma Group	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N	N	\$1,518,000.00
2012-13	Australasian Leukaemia and Lymphoma Group	Support for Cancer Clinical Trials - ALLG	25/06/2010	31/08/2013	N		\$1,549,296.10
2011-12	Australasian Leukaemia and Lymphoma Group	Support for Cancer Clinical Trials	25/06/2010	31/08/2013	N		\$1,549,292.10

2018-19	Australasian Leukaemia and Lymphoma Group	Capacity building support to the Australasian Leukaemia and Lymphoma Group (ALLG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,650,000.00
2019-20	Australasian Leukaemia and Lymphoma Group	Capacity building support to the Australasian Leukaemia and Lymphoma Group (ALLG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,650,000
2017-18	Australasian Leukaemia and Lymphoma Group	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/06/2018	1/09/2021	N	N	\$1,650,000.00
2012-13	Australasian Leukaemia and Lymphoma Group	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,518,000.00
2017-18	Australasian Lung Cancer Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/06/2018	1/09/2021	N	N	\$1,500,000.00
2017-18	Australasian Lung Cancer Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	25/06/2018	31/08/2018	N	N	\$2,300,000.00
2015-16	Australasian Lung Cancer Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2016	N		\$1,380,000.00
2016-17	Australasian Lung Cancer Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2018	N	NA	\$2,300,000.00
2014-15	Australasian Lung Cancer Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,380,000.00
2013-14	Australasian Lung Cancer Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N	N	\$1,380,000.00
2012-13	Australasian Lung Cancer Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,380,000.00
2017-18	Australasian Sarcoma Study Group (through University of Melbourne)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/06/2018	1/09/2021	N	N	\$1,500,000.00
2017-18	Australasian Sarcoma Study Group (through University of Melbourne)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	25/06/2018	31/08/2018	N	N	\$2,299,998.00
2015-16	Australasian Sarcoma Study Group (through University of Melbourne)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2016	N		\$1,379,998.00
2014-15	Australasian Sarcoma Study Group (through University of Melbourne)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,379,998.00
2013-14	Australasian Sarcoma Study Group (through University of Melbourne)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N	N	\$1,379,998.00
2012-13	Australasian Sarcoma Study Group (through University of Melbourne)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,379,998.00
2012-13	Australia and New Zealand Breast Cancer Trials Group	Support for Cancer Clinical Trials - ANZBCTG	25/06/2010	31/08/2013	N		\$1,541,639.00
2015-16	Australia and New Zealand Breast Cancer Trials Group (through Newcastle Innovation Ltd)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2016	N		\$1,517,938.00
2014-15	Australia and New Zealand Breast Cancer Trials Group (through Newcastle Innovation Ltd)	Support for Cancer Clinical Trials Program	26/06/2013	31/08/2016	N		\$1,517,938.00
2013-14	Australia and New Zealand Breast Cancer Trials Group (through Newcastle Innovation Ltd)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N	N	\$1,517,938.00
2012-13	Australia and New Zealand Breast Cancer Trials Group (through Newcastle Innovation Ltd)	Support for Cancer Clinical Trials Program	26/06/2013	31/08/2016	N		\$1,517,938.00
2017-18	Australia and New Zealand Breast Cancer Trials Group (through University of Newcastle Research Associates)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	26/06/2013	31/08/2018	N	N	\$2,529,938.00
2017-18	Australia New Zealand Gynaecological Oncology Group	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	15/06/2017	30/06/2020	N	N	\$132,000.00
2016-17	Australia New Zealand Gynaecological Oncology Group	Supporting People with Cancer Grant Initiative Round 9: Survivors Teaching Students: Saving Women's lives	15/06/2017	30/06/2020	N	NA	\$132,000.00
2017-18	Australia New Zealand Gynaecological Oncology Group (through University of Sydney)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/06/2018	1/09/2021	N	N	\$1,500,000.00
2017-18	Australia New Zealand Gynaecological Oncology Group (through University of Sydney)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	25/06/2018	31/08/2018	N	N	\$2,300,000.00
2015-16	Australia New Zealand Gynaecological Oncology Group (through University of Sydney)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2016	N		\$1,380,000.00
2016-17	Australia New Zealand Gynaecological Oncology Group (through University of Sydney)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2018	N	NA	\$2,300,000.00
2014-15	Australia New Zealand Gynaecological Oncology Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,380,000.00
2013-14	Australia New Zealand Gynaecological Oncology Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N	N	\$1,380,000.00

2012-13	Australia New Zealand Gynaecological Oncology Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,380,000.00
2013-14	Australia Post	Contract mail rates between Australia Post and Cancer Australia	1/08/2012	30/06/2015	N	N	\$120,976.00
2017-18	Australia and New Zealand Melanoma Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/06/2018	1/09/2021	N	N	\$1,500,000.00
2017-18	Australia and New Zealand Melanoma Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	25/06/2018	31/08/2018	N	N	\$2,300,000.00
2015-16	Australia and New Zealand Melanoma Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2016	N		\$1,380,000.00
2016-17	Australia and New Zealand Melanoma Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2018	N	NA	\$2,300,000.00
2014-15	Australia and New Zealand Melanoma Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,380,000.00
2013-14	Australia and New Zealand Melanoma Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N	N	\$1,380,000.00
2012-13	Australia and New Zealand Melanoma Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,380,000.00
2018-19	Australian and New Zealand Breast Cancer Trials Group	Capacity building support to the Breast Cancer Trials (BCT) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,644,089.10
2017-18	Australian and New Zealand Children's Haematology/Oncology Group (through Monash University)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/06/2018	1/09/2021	N	N	\$1,500,000.00
2017-18	Australian and New Zealand Children's Haematology/Oncology Group (through Monash University)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	25/06/2018	31/08/2018	N	N	\$2,369,173.00
2015-16	Australian and New Zealand Children's Haematology/Oncology Group (through Monash University)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2017	N		\$1,839,173.00
2013-14	Australian and New Zealand Children's Haematology/Oncology Group (through Monash University)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N	N	\$1,379,173.00
2012-13	Australian and New Zealand Children's Haematology/Oncology Group (through Monash University)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,379,173.00
2014-15	Australian and New Zealand Children's Haematology/Oncology Group (through Monsh University)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,379,173.00
2011-12	Australian and New Zealand Children's Haematology and Oncology Group	Support for Cancer Clinical Trials	25/06/2010	30/06/2013	N		\$1,547,700.00
2017-18	Australian and New Zealand Urogenital and Prostate Cancer Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/06/2018	1/09/2021	N	N	\$1,500,000.00
2017-18	Australian and New Zealand Urogenital and Prostate Cancer Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	25/06/2018	31/08/2018	N	N	\$2,300,000.00
2015-16	Australian and New Zealand Urogenital and Prostate Cancer Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2016	N		\$1,380,000.00
2016-17	Australian and New Zealand Urogenital and Prostate Cancer Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2018	N	NA	\$2,300,000.00
2014-15	Australian and New Zealand Urogenital and Prostate Cancer Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,380,000.00
2013-14	Australian and New Zealand Urogenital and Prostate Cancer Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N	N	\$1,380,000.00
2012-13	Australian and New Zealand Urogenital and Prostate Cancer Trials Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,380,000.00
2012-13	Australian Institute of Health and Welfare	Statistical Overviews of lung cancer in Australia, endometrial/cervical in Australia and cancers in Aboriginal and Torres Strait Islander people	21/06/2010	30/06/2013	N		\$717,383.70
2012-13	Australian Institute of Health and Welfare	Statistical Overviews of cancers in Australia	25/06/2010	30/06/2013	N		\$717,383.00
2011-12	Australian Institute of Health and Welfare	Statistical Overviews of lung cancer in Australia, endometrial/cervical in Australia and cancers in Aboriginal and Torres Strait Islander people	21/06/2010	30/06/2013	N		\$148,897.10
2011-12	Australian Institute of Health and Welfare	Statistical Overviews of lung cancer in Australia, endometrial/cervical in Australia and cancers in Aboriginal and Torres Strait Islander people	25/06/2010	30/06/2012	N		\$717,383.00
2017-18	Australian National University	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	25/04/2017	24/07/2020	N	N	\$574,009.00
2017-18	Australian National University	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/05/2015	30/07/2018	N	N	\$599,492.00
2015-16	Australian National University	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2012: EQUIVALENCE OF SUN EXPOSURE AND VITAMIN D SUPPLEMENTATION IN VITAMIN D INSUFFICIENCY. APPL ID 1045198	1/03/2013	31/08/2017	N		\$582,911.00

2015-16	Australian National University	2014 PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): NOVEL COMBINATION THERAPIES TARGETING THE RIBOSOME TO TREAT PROSTATE CANCER (PC). APP. 1085456	1/05/2015	30/07/2018	N		\$599,492.00
2016-17	Australian National University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: AUTO-CHECK study: Molecular determinants of autoimmunity and immune related adverse events in advanced cancer patients treated with immune checkpoint inhibitors: ID1130330	25/04/2017	24/07/2020	N	NA	\$574,009.00
2016-17	Australian National University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Equivalence of sun exposure and vitamin D supplementation in vitamin D insufficiency. Appl ID 1045198	1/03/2013	31/03/2018	N	NA	\$582,911.00
2016-17	Australian National University	2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Novel combination therapies targeting the ribosome to treat prostate cancer (PC). App. 1084546	1/05/2015	30/07/2018	N	NA	\$599,492.00
2014-15	Australian National University	Priority Driven Collaborative Cancer Research Scheme 2012: Equivalence of sun exposure and vitamin D supplementation in vitamin D insufficiency.	1/03/2013	31/05/2016	N		\$582,911.00
2014-15	Australian National University	2014 Priority Driven Collaborative Cancer Research Scheme: Novel combination therapies targeting the ribosome to treat prostate cancer.	28/04/2015	30/07/2018	N		\$599,492.00
2013-14	Australian National University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Equivalence of sun exposure and vitamin D supplementation in vitamin D insufficiency. Appl ID 1045198	1/03/2013	31/05/2016	N	N	\$582,911.00
2012-13	Australian National University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Targeting of two Aspects of Metabolism (TOTAM) for cancer therapy	16/02/2011	31/05/2014	N		\$546,165.40
2012-13	Australian National University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Equivalence of sun exposure and vitamin D supplementation in vitamin D insufficiency. Appl ID 1045198	1/03/2013	31/05/2016	N		\$582,911.00
2011-12	Australian National University	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Targeting of two Aspects of Metabolism (TOTAM) for cancer therapy	16/02/2011	28/02/2014	N		\$546,165.40
2019-20	Australian National University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: AUTO-CHECK study: Molecular determinants of autoimmunity and immune related adverse events in advanced cancer patients treated with immune checkpoint inhibitors. APPID: 1130330-Cook	25/04/2017	24/01/2022	N	N	\$574,009
2011-12	Bendigo Health Care Group	Rural & Remote Network	23/02/2009	31/08/2011	N		\$219,350.79
2011-12	Border Medical Oncology Research	To implement a portfolio of active industry-independent trials undertaken by Australia's National Multi-site Collaborative National Cancer Clinical Trials Groups, thereby increasing access to clinical trials in regional Australia	1/02/2009	31/08/2011	N		\$310,215.86
2017-18	Breast Cancer Network Australia	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	11/07/2017	30/06/2020	N	N	\$2,269,885.58
2015-16	BREAST CANCER NETWORK AUSTRALIA	SUPPORTING WOMEN IN RURAL AREAS DIAGNOSED WITH BREAST CANCER (SWRADBC) PROGRAM	1/08/2014	30/06/2017	N		\$2,619,100.00
2015-16	BREAST CANCER NETWORK AUSTRALIA	SUPPORTING PEOPLE WITH CANCER (SPWC) 2015 - DEVELOP AND DISSEMINATE EVIDENCE-BASED, CULTURALLY APPROPRIATE AND IN-LANGUAGE RESOURCES FOR GREEK AND CHINESE WOMEN AFFECTED BY SECONDARY BREAST CANCER.	30/06/2015	30/06/2018	N		\$131,552.30
2016-17	Breast Cancer Network Australia	SPWC - Develop and disseminate evidence-based, culturally appropriate and in-language resources for Greek and Chinese women affected by secondary breast cancer.	30/06/2015	30/06/2018	N	NA	\$131,552.30
2014-15	Breast Cancer Network Australia	Supporting Women in Rural Areas Diagnosed with Breast Cancer Program	1/08/2014	31/10/2017	N		\$2,619,100.00
2014-15	Breast Cancer Network Australia	Supporting People with Cancer - Develop and disseminate evidence-based, culturally appropriate and in-language resources for Greek and Chinese women affected by secondary breast cancer.	30/06/2015	30/06/2018	N		\$131,552.30
2012-13	Breast Cancer Network Australia	Funding breast Cancer Network Australia	4/11/2011	30/06/2014	N		\$1,366,200.00
2012-13	Breast Cancer Network Australia	My Journey Kit	18/08/2009	30/06/2015	N		\$1,490,500.00
2012-13	Breast Cancer Network Australia	Hope and Hurdles Pack	18/08/2009	30/06/2015	N		\$990,000.00
2011-12	Breast Cancer Network Australia	Funding breast Cancer Network Australia	4/11/2011	30/06/2014	N		\$1,366,200.00
2011-12	Breast Cancer Network Australia	My Journey Kit	23/02/2012	1/09/2012	N		\$248,600.00
2011-12	Breast Cancer Network Australia	Hope and Hurdles Pack (transferred from NBOCC)	1/02/2012	30/06/2012	N		\$165,000.00
2017-18	Breast Cancer Trials (BCT) through ANZ Breast Cancer Trials Group Ltd	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/06/2018	1/09/2021	N	N	\$1,644,040.00
2012-13	Breast Surgeons Society of Australia and New Zealand	Explore predictors of survival outcomes from breast cancer	18/04/2012	30/06/2013	N		\$142,521.51
2011-12	Breast Surgeons Society of Australia and New Zealand	Explore predictors of survival outcomes from breast cancer	18/04/2012	18/04/2013	N		\$117,771.50
2017-18	Cancer Council Australia	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	27/03/2017	30/06/2020	N	N	\$128,405.00

2015-16	CANCER COUNCIL AUSTRALIA	SUPPORTING PEOPLE WITH CANCER (SPWC) 2015 - DEVELOP A CULTURALLY-SPECIFIC AND ACCESSIBLE WEB-BASED RESOURCE TO MEET THE IDENTIFIED NEEDS OF SPECIFIC CALD COMMUNITIES AFFECTED BY CANCER.	30/06/2015	30/06/2018	N		\$132,000.00
2016-17	Cancer Council Australia	Supporting people with cancer Grant initiative: Production of psychosocial and information resources for Australians with less common cancers.	27/03/2017	30/06/2020	N	NA	\$128,405.00
2016-17	Cancer Council Australia	SPWC - Develop a culturally-specific and accessible web-based resource to meet the identified needs of specific CALD communities affected by cancer.	30/06/2015	30/06/2018	N	NA	\$132,000.00
2014-15	Cancer Council Australia	Supporting People with Cancer - Develop a culturally-specific and accessible web-based resource to meet the identified needs of specific culturally and linguistically diverse communities affected by cancer.	30/06/2015	30/06/2018	N		\$132,000.00
2011-12	Cancer Council Australia	Creating Wikipedia-based Clinical Practice Guidelines for the Prevention, Diagnosis and Management of Lung Cancer Project	4/03/2010	30/06/2012	N		\$253,528.00
2011-12	Cancer Council Australia	Development of Clinical Practice Guidelines for the Treatment of Women with Gynaecological Cancers	18/06/2010	30/06/2012	N		\$175,120.00
2019-20	Cancer Council Australia	Supporting People with Cancer Grant Initiative:: Production of psychosocial and information resources for Australians with less common cancers	27/03/2017	30/09/2020	N	N	\$128,405
2017-18	Cancer Council NSW	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2017	29/09/2020	N	N	\$579,140.00
2015-16	CANCER COUNCIL NSW	SUPPORTING PEOPLE WITH CANCER (SPWC) 2015 - DEVELOP AND IMPLEMENT ONLINE, AUDIO-VISUAL WEBINAR INFORMATION SESSIONS IN MANDARIN AND CANTONESE TO ADDRESS THE UNMET NEEDS OF PEOPLE IN THE CHINESE COMMUNITY WHO ARE AFFECTED BY CANCER; AND COMPILER EXISTING SUPPORTIVE CARE SERVICES AND RESOURCES AVAILABLE TO THE CHINESE COMMUNITY.	9/06/2015	30/06/2018	N		\$122,100.00
2016-17	Cancer Council NSW	SPWC - Develop and implement online, audio-visual webinar information sessions in Mandarin and Cantonese to address the unmet needs of people in the Chinese community who are affected by cancer; and compile existing supportive care services and resources available to the Chinese community.	9/06/2015	30/06/2018	N	NA	\$122,100.00
2014-15	Cancer Council NSW	Supporting People with Cancer - Develop and implement online, audio-visual webinar information sessions in Mandarin and Cantonese to address the unmet needs of people in the Chinese community who are affected by cancer; and compile existing supportive care services and resources available to the Chinese community.	9/06/2015	30/06/2018	N		\$122,100.00
2019-20	Cancer Council NSW	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Hide and seek with hereditary cancer: Improving detection of colorectal cancer patients with a high risk of Lynch syndrome. APPID: 1123924-Taylor	30/06/2017	29/09/2021	N	N	\$579,140
2015-16	CANCER COUNCIL Queensland	SUPPORTING PEOPLE WITH CANCER (SPWC) 2015 - DESIGN AND DELIVER EVIDENCE-BASED CANCER CONTROL COURSES FOR ABORIGINAL AND TORRES STRAIT ISLANDER HEALTH WORKERS AND BUILD LOCAL CANCER SUPPORT NETWORKS FOR ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLE AFFECTED BY CANCER LIVING IN REGIONAL AND RURAL QUEENSLAND.	30/06/2015	30/06/2018	N		\$132,000.00
2016-17	Cancer Council Queensland	SPWC - Design and deliver evidence-based cancer control courses for Aboriginal and Torres Strait Islander health workers and build local cancer support networks for Aboriginal and Torres Strait Islander people affected by cancer living in regional and rural Queensland.	30/06/2015	30/06/2018	N	NA	\$132,000.00
2014-15	Cancer Council Queensland	Supporting People with Cancer - Design and deliver evidence-based cancer control courses for Aboriginal and Torres Strait Islander health workers and build local cancer support networks for Aboriginal and Torres Strait Islander people affected by cancer living in regional and rural Queensland.	30/06/2015	30/06/2018	N		\$132,000.00
2012-13	Cancer Council Queensland	Research and report on the effects of stigma and nihilistic views on lung cancer outcomes	1/02/2011	11/10/2013	N		\$632,259.00
2012-13	Cancer Council Queensland	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010 - A multi-level investigation of inequalities in clinical and psychosocial outcomes for women after breast cancer	8/02/2011	31/05/2014	N		\$647,619.50
2011-12	Cancer Council Queensland	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010 - A multi-level investigation of inequalities in clinical and psychosocial outcomes for women after breast cancer	8/02/2011	28/02/2014	N		\$647,619.50
2011-12	Cancer Council Queensland	Research and report on the effects of stigma and nihilistic views on lung cancer outcomes	16/02/2011	31/05/2013	N		\$588,112.00
2011-12	Cancer Council Queensland	Improving the Psychosocial Health of People with Cancer and their Carers: A Community-Based Approach	31/01/2009	30/12/2012	N		\$297,156.20

2017-18	Cancer Council Victoria	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	21/06/2017	30/06/2020	N	N	\$131,230.00
2016-17	Cancer Council Victoria	Supporting People with Cancer Grant Initiative: Keeping Things on Track	21/06/2017	30/06/2020	N	NA	\$131,230.00
2012-13	Cancer Council Victoria	Capturing information on clinical stage, metastases at diagnosis and cancer recurrence employing IT solutions	15/04/2010	30/06/2013	N		\$1,622,499.00
2011-12	Cancer Council Victoria	Capturing information on clinical stage, metastases at diagnosis and cancer recurrence employing IT solutions	15/04/2010	30/06/2013	N		\$1,676,398.90
2011-12	Cancer Council Victoria	A web-based intervention to reduce distress and improve quality of life among younger women with breast cancer: A RCT	15/12/2008	31/01/2012	N		\$105,097.18
2019-20	Cancer Council Victoria	Supporting People with Cancer Grant Initiative: Keeping Things on Track	13/06/2017	30/06/2021	N	N	\$131,230
2011-12	Cancer Institute NSW	The continuation of Cancer Service Networks National Demonstration Program (CanNET) in New South Wales	10/02/2010	30/06/2012	N		\$932,091.60
2011-12	Cancer Institute NSW	Maintaining the eviQ Primary Health Care modules	1/03/2011	30/06/2012	N		\$119,900.00
2011-12	Cancer Trials Australia	National regional co-ordinating secretariat	1/04/2009	31/08/2011	N		\$350,821.09
2017-18	CanTeen	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	16/03/2018	30/03/2021	N	N	\$132,000.00
2011-12	Canteen	Project AYA - National (Creation of a national data set)	27/11/2009	31/05/2012	N		\$352,000.00
2019-20	CanTeen	Supporting people with cancer Grant initiative - Improving health information and involvement outcomes for adolescent and young adult cancer patients: A Youth Cancer Services system-wide approach	16/03/2018	30/06/2021	N	N	\$132,000
2013-14	CBRE Pty Ltd	Lease for Level 14, 300 Elizabeth St, Surry Hills NSW 2010	1/10/2011	28/02/2015	N	N	\$3,292,893.13
2019-20	Central Adelaide Local Health Network (CALHN)	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Predicting and improving anti-tumour responses to immunotherapy in advanced cancer patients. APPID: 1186306-Ebert	01/06/2020	31/08/2023	N	N	\$560,142
2017-18	Children's Cancer Institute Australia	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	3/03/2017	2/06/2020	N	N	\$296,428.50
2017-18	Children's Cancer Institute Australia	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	27/03/2017	26/06/2020	N	N	\$496,055.50
2016-17	Children's Cancer Institute Australia	Priority Driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Reversing glucocorticoid resistance in paediatric acute lymphoblastic leukaemia - a novel epigenetic mechanism linked to lymphocyte-specific chromatin conformation: ID1129129	10/03/2017	9/06/2020	N	NA	\$296,428.50
2016-17	Children's Cancer Institute Australia	Priority Driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Targeting FACT to inhibit MYCN-driven transcription in neuroblastoma: ID1123235	27/03/2017	26/06/2020	N	NA	\$496,055.50
2012-13	Chill IT	IT Maintenance and Support	1/07/2012	1/06/2015	N		\$699,339.30
2011-12	Chill IT	IT Maintenance and Support	1/07/2012	1/06/2015	N		\$699,339.30
2013-14	Chill IT Pty Ltd	IT Maintenance and Support	1/07/2012	1/06/2015	N	N	\$699,339.30
2011-12	Clinical Oncology Society of Australia	Building Cancer Support Networks Initiative - Better Cancer Support through Consumers (BCSN)	30/03/2012	30/11/2012	N		\$297,000.00
2013-14	Closed Loop Design Pty Ltd	Provide expert evidence-based advice and translational research input into a range of agreed Business Plan projects across the organisation.	15/07/2014	30/06/2015	N	N	\$126,720.00
2017-18	Cooperative Trials Group for Neuro-Oncology (through University of Sydney)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/06/2018	1/09/2021	N	N	\$1,500,000.00
2017-18	Cooperative Trials Group for Neuro-Oncology (through University of Sydney)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	25/06/2018	31/08/2018	N	N	\$2,299,859.00
2015-16	COOPERATIVE TRIALS GROUP FOR NEURO-ONCOLOGY (THROUGH UNIVERSITY OF SYDNEY)	SUPPORT FOR CANCER CLINICAL TRIALS PROGRAM	1/07/2013	31/08/2016	N		\$1,379,859.00
2016-17	Cooperative Trials Group for Neuro-Oncology (through University of Sydney)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2018	N	NA	\$2,299,859.00
2014-15	Cooperative Trials Group for Neuro-Oncology (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,379,859.00
2013-14	Cooperative Trials Group for Neuro-Oncology (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N	N	\$1,379,859.00
2012-13	Cooperative Trials Group for Neuro-Oncology (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,379,859.00
2017-18	Curtin University of Technology	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	6/04/2016	6/07/2019	N	N	\$535,789.00
2015-16	CURTIN UNIVERSITY OF TECHNOLOGY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PdCCRS) 2015: CONFIDENCE TO CARE: A MULTI-STATE RANDOMISED CONTROLLED TRIAL OF STRUCTURED NURSE-LED HOME-BASED SUPPORT AND EDUCATION FOR CARERS OF PEOPLE WITH HIGH GRADE GLIOMA.: ID1105307	6/04/2016	6/07/2019	N		\$535,789.00

2016-17	Curtin University of Technology	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2015: Confidence to Care: A multi-state randomised controlled trial of structured nurse-led home-based support and education for carers of people with high grade glioma.: ID1105307	6/04/2016	6/07/2019	N	NA	\$535,789.00
2014-15	Curtin University of Technology	Priority Driven Collaborative Cancer Research Scheme 2010: Meeting the education and support needs of women with breast cancer who are referred for radiotherapy: A multiple - baseline study.	1/03/2011	1/03/2016	N		\$220,993.30
2013-14	Curtin University of Technology	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Meeting the education and support needs of women with breast cancer who are referred for radiotherapy: A multiple - baseline study	1/03/2011	1/10/2015	N	N	\$220,993.30
2012-13	Curtin University of Technology	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Meeting the education and support needs of women with breast cancer who are referred for radiotherapy: A multiple - baseline study	13/06/2011	31/12/2014	N		\$220,993.30
2011-12	Curtin University of Technology	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Meeting the education and support needs of women with breast cancer who are referred for radiotherapy: A multiple - baseline study	13/06/2011	31/12/2014	N		\$220,993.30
2019-20	Curtin University of Technology	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: Confidence to Care: A multi-state randomised controlled trial of structured nurse led home-based support and education for carers of people with high grade glioma. APPID: 1105307-Halkett	06/04/2016	31/08/2020	N	N	\$535,789
2014-15	Edith Cowan University	2011 Priority Driven Collaborative Cancer Research Scheme- Can exercise ameliorate treatment toxicity during the initial phase of testosterone suppression in prostate patients? Is this more effective than delayed rehabilitation and what is the time course and persistence of benefits?	2/02/2012	31/03/2016	N		\$163,634.55
2013-14	Edith Cowan University	2011 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - Can exercise ameliorate treatment toxicity during the initial phase of testosterone suppression in prostate patients? Is this more effective than delayed rehabilitation and what is the time course and persistence of benefits?	2/02/2012	28/05/2015	N	N	\$163,634.55
2012-13	Edith Cowan University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Can exercise ameliorate treatment toxicity during the initial phase of testosterone suppression in prostate patients?	2/02/2012	28/05/2015	N		\$163,634.55
2011-12	Edith Cowan University	2011 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - Can exercise ameliorate treatment toxicity during the initial phase of testosterone suppression in prostate patients? Is this more effective than delayed rehabilitation and what is the time course and persistence of benefits?	2/02/2012	28/02/2015	N		\$163,634.55
2012-13	Finsbury Green	Printing of 'Guide for Women with Early Breast Cancer' and 'Guide for Women with Secondary Breast Cancer'.	4/06/2013	30/06/2013	N		\$203,894.00
2011-12	Flight Centre Management (FCM) Travel Solutions	Air travel services	6/12/2010	30/04/2013	N		\$443,333.34
2018-19	Flinders University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Personalising treatment and surveillance for colorectal cancer: prognostication with the circulating tumour-derived methylated DNA markers BCAT1 and IKZF1 AppID: 1161720 - SYMONDS	01/06/2019	31/08/2022	N	N	\$553,196.00
2019-20	Flinders University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Increasing resilience and reducing smoking for lower socio-economic groups. APPID: 1182598-Ward	01/06/2020	31/08/2023	N	N	\$553,820
2019-20	Flinders University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Personalising treatment and surveillance for colorectal cancer: prognostication with the circulating tumour-derived methylated DNA markers BCAT1 and IKZF1 AppID: 1161720 - SYMONDS	01/06/2019	31/08/2022	N	N	\$553,196
2017-18	Garvan Institute of Medical Research	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	15/02/2016	15/05/2019	N	N	\$600,000.00
2017-18	Garvan Institute of Medical Research	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2016	30/09/2019	N	N	\$449,150.00
2017-18	Garvan Institute of Medical Research	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	15/03/2018	14/06/2021	N	N	\$300,000.00
2015-16	GARVAN INSTITUTE OF MEDICAL RESEARCH	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): FROM FUNCTIONAL GENOMICS TO PRECISION MEDICINE: THE THERAPEUTIC POTENTIAL OF TARGETING RHO/ROCK SIGNALLING IN PANCREATIC CANCER. APP1065022	21/02/2014	20/05/2017	N		\$599,997.00
2015-16	GARVAN INSTITUTE OF MEDICAL RESEARCH	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2015: FROM MICE TO MEN: BIOMARKER-DRIVEN CLASSIFICATION OF PANCREATIC CANCER TO DEFINE THE GEMCITABINE/ NAB-PACLITAXEL-RESPONSIVE MOLECULAR SUBTYPE: ID1100722	15/02/2016	15/05/2019	N		\$600,000.00

2015-16	GARVAN INSTITUTE OF MEDICAL RESEARCH	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2015: A NOVEL APPROACH TO OVERCOME TREATMENT-RESISTANCE IN BREAST CANCER: ID1107170	30/06/2016	30/09/2019	N		\$449,150.00
2016-17	Garvan Institute of Medical Research	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2015: From mice to men: biomarker-driven classification of pancreatic cancer to define the gemcitabine/nab-paclitaxel-responsive molecular subtype: ID1100722	15/02/2016	15/05/2019	N	NA	\$600,000.00
2016-17	Garvan Institute of Medical Research	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2015: A novel approach to overcome treatment-resistance in breast cancer: ID1107170	30/06/2016	30/09/2019	N	NA	\$415,770.00
2014-15	Garvan Institute of Medical Research	2013 Priority-driven Collaborative Cancer Research Scheme: From functional genomics to precision medicine: The therapeutic potential of targeting Rho/ROCK signalling in pancreatic cancer.	17/02/2014	20/05/2017	N		\$599,997.00
2013-14	Garvan Institute of Medical Research	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): From functional genomics to precision medicine: The therapeutic potential of targeting Rho/ROCK signalling in pancreatic cancer. App1065022	17/02/2014	20/05/2017	N	N	\$599,997.00
2011-12	Garvan Institute of Medical Research	DNA methylation alterations as detection markers for early ovarian cancer	2/02/2009	31/01/2012	N		\$639,375.00
2011-12	Garvan Institute of Medical Research	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Identifying and targeting Docetaxel resistance in hormone refractory prostate cancer	12/01/2010	31/01/2013	N		\$213,950.00
2019-20	Garvan Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Dual targeting of Src and JAK/STAT3 signalling as a novel personalized treatment strategy for pancreatic cancer APPID: 1143699-Pajic	15/03/2018	14/06/2021	N	N	\$300,000
2012-13	Griffith University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: ProCan for Life: A Multimodal Supportive Care Intervention for Men with Prostate Cancer	24/01/2011	30/01/2014	N		\$329,006.70
2011-12	Griffith University	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) ProCan for Life: A Multimodal Supportive Care Intervention for Men with Prostate Cancer	24/01/2011	30/01/2014	N		\$329,006.70
2011-12	Health Issues Centre Incorporated	National framework for consumer involvement in cancer control: resource tool kit	19/03/2012	30/09/2012	N		\$187,624.00
2013-14	HealthCare Management Advisors Pty Ltd	To engage a consultant to undertake an environmental scan of service delivery models in gynaecological cancer across Australia, and report on the national applicability of select models	19/05/2014	29/08/2014	N	N	\$143,727.00
2013-14	Intermediary Contracting Pty Ltd	Web development and technical support	1/07/2013	30/06/2014	N	N	\$104,577.00
2012-13	Investa	Lease for Level 14 300 Elizabeth St, Surry Hills NSW 2010	1/10/2011	28/02/2015	N		\$3,292,893.13
2011-12	KPMG	Financial Management services	18/07/2011	24/02/2012	N		\$267,413.64
2011-12	KPMG	Financial Management services - financial advice & move to Sydney	6/12/2011	24/02/2012	N		\$121,000.00
2017-18	La Trobe University	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	16/03/2018	30/06/2021	N	N	\$132,000.00
2017-18	La Trobe University	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2018	29/09/2021	N	N	\$598,677.00
2017-18	La Trobe University	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	28/06/2016	27/09/2019	N	N	\$430,563.00
2017-18	La Trobe University	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/07/2014	30/03/2019	N	N	\$280,000.00
2015-16	LA TROBE UNIVERSITY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2015: A MULTISTAGE MULTI CENTRE INTERNATIONAL RANDOMISED TRIAL OF CONVENTIONAL CARE OR RADIOABLATION(STEREOTACTIC BODY RADIOTHERAPY) FOR EXTRA-CRANIAL OLIGOMETASTATIC DISEASE IN LUNG, BREAST AND PROSTATE CANCER (CORE): ID1104569	28/06/2016	27/09/2019	N		\$430,563.00
2016-17	La Trobe University	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): A Randomised phase II trial of Adaptive Image guided standard or Dose Escalated Radiotherapy in the treatment of transitional cell carcinoma of the Bladder (RAIDER-B). App1063072	1/07/2014	30/03/2019	N	NA	\$560,000.00
2016-17	La Trobe University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2015: A multistage multi centre international randomised trial of Conventional care Or Radioablation(stereotactic body radiotherapy) for Extra-cranial oligometastatic disease in lung, breast and prostate cancer (CORE): ID1104569	28/06/2016	27/09/2019	N	NA	\$430,563.00
2018-19	La Trobe University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) international 2019: Tackling breast cancer heterogeneity for the complete eradication of metastases-MERINO	15/05/2019	15/08/2022	N	N	\$300,000.00
2019-20	La Trobe University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) international 2018: Tackling breast cancer heterogeneity for the complete eradication of metastases. AppID: CCR19606878-MERINO	15/05/2019	15/08/2022	N	N	\$300,000
2019-20	La Trobe University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Improving Immune Checkpoint Treatment of Colorectal Cancer by STAT3 inhibition APPID: 1144460-Ernst	30/06/2018	29/08/2021	N	N	\$598,677

2019-20	La Trobe University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: A multistage multi centre international randomised trial of Conventional care Or Radioablation (stereotactic body radiotherapy) for Extra-cranial oligometastatic disease in lung, breast and prostate cancer (CORE). APPID: 1104569 Foroudi	28/06/2016	31/03/2021	N	N	\$430,563
2011-12	Leukaemia Foundation of Australia	Priority Driven Collaborative Cancer Research Scheme (PDCCRS)	19/09/2008	18/09/2011	N		\$330,000.00
2013-14	Ludwig Institute of Cancer Research	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Discovery of colorectal cancer subtype associated tumour suppressor genes using next-generation sequencing and high throughput functional genomics	2/02/2012	1/05/2015	N	N	\$482,476.50
2013-14	Ludwig Institute of Cancer Research	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Identifying therapeutic targets by profiling DNA repair in lung cancer	9/02/2011	31/03/2015	N	N	\$552,776.40
2012-13	Ludwig Institute of Cancer Research	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Discovery of colorectal cancer subtype associated tumour suppressor genes using next-generation sequencing and high throughput functional genomics	2/02/2012	1/05/2015	N		\$482,476.50
2011-12	Ludwig Institute of Cancer Research	2011 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - Discovery of colorectal cancer subtype associated tumour suppressor genes using next-generation sequencing and high throughput functional genomics	2/02/2012	1/02/2015	N		\$482,476.50
2011-12	Ludwig Institute of Cancer Research	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Mechanisms of abiraterone resistance in prostate cancer	18/01/2010	28/02/2013	N		\$216,150.00
2017-18	Lung Foundation Australia	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	28/01/2016	1/03/2019	N	N	\$132,000.00
2015-16	LUNG FOUNDATION AUSTRALIA	SUPPORTING PEOPLE WITH CANCER (SPWC) 2015 - ESTABLISH A NEW NURSE-LED LUNG CANCER SUPPORT SERVICE TO PROVIDE CLINICALLY-BASED, PATIENT-CENTRED SUPPORT FOR PEOPLE AFFECTED BY LUNG CANCER AND MESOTHELIOMA, INCLUDING THOSE IN REGIONAL AND RURAL LOCATIONS.	4/06/2015	30/06/2018	N		\$132,000.00
2015-16	LUNG FOUNDATION AUSTRALIA	SUPPORTING PEOPLE WITH CANCER (SPWC) 2016: THIS PROJECT WILL DEVELOP AND DELIVER A SET OF PATIENT-CENTRED EVIDENCE BASED WEBINARS TO IMPROVE HEALTH LITERACY AND ASSIST PATIENTS TO MORE EFFECTIVE SELF-MANAGE THEIR CONDITION AND CONNECT THEM WITH THE SERVICES THEY NEED.	28/01/2016	1/03/2019	N		\$132,000.00
2016-17	Lung Foundation Australia	SPWC - Establish a new Nurse-Led Lung Cancer Support Service to provide clinically-based, patient-centred support for people affected by lung cancer and mesothelioma, including those in regional and rural locations.	4/06/2015	30/06/2018	N	NA	\$132,000.00
2016-17	Lung Foundation Australia	This project will develop and deliver a set of patient-centred evidence based webinars to improve health literacy and assist patients to more effective self-manage their condition and connect them with the services they need.	28/01/2016	1/03/2019	N	NA	\$132,000.00
2014-15	Lung Foundation Australia	Supporting People with Cancer - Establish a new Nurse-Led Lung Cancer Support Service to provide clinically-based, patient-centred support for people affected by lung cancer and mesothelioma, including those in regional and rural locations.	4/06/2015	30/06/2018	N		\$132,000.00
2016-17	Macquarie University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Hide and seek with hereditary cancer: Improving detection of colorectal cancer patients with a high risk of Lynch syndrome: ID1123924	30/06/2017	29/09/2020	N	NA	\$637,054.00
2012-13	Macquarie University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Evaluation of an online decision aid for women with breast cancer considering reconstructive surgery	30/01/2009	30/04/2014	N		\$103,803.34
2011-12	Macquarie University	Evaluation of an online decision aid for women with breast cancer considering reconstructive surgery	30/01/2009	31/01/2012	N		\$103,803.34
2011-12	Mater Medical Research Institute Ltd	RNA Loading of Tumour Associated Antigens and the Activation of Blood Dendritic Cells for Prostate Cancer Immunotherapy	9/01/2009	31/12/2012	N		\$327,195.00
2017-18	Melbourne Health	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2016	30/09/2019	N	N	\$290,340.50
2015-16	MELBOURNE HEALTH	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2015: CAPP3: A RANDOMIZED DOUBLE BLIND DOSE INFERIORITY TRIAL OF ASPIRIN IN LYNCH SYNDROME: ID1103035	30/06/2016	30/09/2019	N		\$290,340.50
2016-17	Melbourne Health	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2015: CaPP3: a randomized double blind dose inferiority trial of aspirin in Lynch Syndrome: ID1103035	30/06/2016	30/09/2019	N	NA	\$290,340.50
2012-13	Melbourne Health	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Resveratrol in the chemoprevention of colorectal neoplasia	3/02/2009	3/05/2014	N		\$575,750.00
2011-12	Melbourne Health	Resveratrol in the chemoprevention of colorectal neoplasia	3/01/2009	3/02/2013	N		\$633,325.00
2019-20	Melbourne Health	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: CaPP3: a randomized double blind dose inferiority trial of aspirin in Lynch Syndrome. APPID: 1103035-Macrae	30/06/2016	30/09/2020	N	N	\$290,341
2011-12	Menzies Research Institute	Integrative genomic approaches to understanding the genetics of prostate cancer	14/01/2009	14/11/2012	N		\$567,270.00

2017-18	Menzies School of Health Research	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/01/2016	1/03/2019	N	N	\$131,472.00
2015-16	MENZIES SCHOOL OF HEALTH RESEARCH	SUPPORTING PEOPLE WITH CANCER (SPWC) 2016:THIS PROJECT WILL DEVELOP A KNOWLEDGE TRANSFER AND IMPLEMENTATION FRAMEWORK FOR SUPPORTIVE CARE NEEDS FOR INDIGENOUS AUSTRALIAN ALONG THE CANCER CONTINUUM.	29/01/2016	1/03/2019	N		\$131,472.00
2016-17	Menzies School of Health Research	This project will develop a knowledge transfer and implementation framework for supportive care needs for Indigenous Australian along the cancer continuum.	29/01/2016	1/03/2019	N	NA	\$131,472.00
2019-20	Monash / Australia and New Zealand Melanoma Trials Group	2019 Supporting People with Cancer Round 11: Improving Melanoma and Skin Cancer awareness in regional and rural Australia. The Project will develop and deliver patient and consumer centred resources and improve access to quality, coordinated and sustainable melanoma and skin cancer support networks for all Australians.	07/03/2019	30/05/2022	N	N	\$132,000
2018-19	Monash /Australia and New Zealand Melanoma Trials Group	2019 Supporting People with Cancer Round 11	07/03/2019	30/05/2022	N	N	\$132,000.00
2013-14	Monash Health	Procurement of evaluation data: Shared follow-up care for women with early breast cancer 2013-2015	24/06/2013	15/09/2015	N	N	\$126,720.00
2017-18	Monash University	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	27/10/2017	30/06/2021	N	N	\$871,449.00
2017-18	Monash University	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	27/10/2017	31/12/2019	N	N	\$506,419.00
2017-18	Monash University	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	16/04/2018	15/07/2021	N	N	\$597,557.00
2015-16	MONASH UNIVERSITY	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): AN INHALABLE DENDRIMER-BASED DELIVERY PLATFORM FOR THE TARGETED TREATMENT OF PRIMARY AND SECONDARY LUNG CANCERS. APP1070184	1/05/2014	30/07/2017	N		\$452,383.00
2016-17	Monash University	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): An inhalable dendrimer-based delivery platform for the targeted treatment of primary and secondary lung cancers. App1070184	1/05/2014	30/07/2017	N	NA	\$452,383.00
2014-15	Monash University	Priority Driven Collaborative Cancer Research Scheme 2012: Defining Epigenetic Changes in Prostate Cancer Stroma.	1/03/2013	30/06/2016	N		\$597,987.00
2014-15	Monash University	2013 Priority-driven Collaborative Cancer Research Scheme: An inhalable dendrimer-based delivery platform for the targeted treatment of primary and secondary lung cancers.	23/04/2014	30/07/2017	N		\$452,383.00
2013-14	Monash University	Investigating symptoms of lung cancer - a guide for general practitioners	1/02/2011	31/12/2016	N	N	\$941,620.00
2013-14	Monash University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Determining the causes of observed variation in survival after diagnosis of prostate cancer	30/05/2011	30/09/2014	N	N	\$627,607.20
2013-14	Monash University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Defining Epigenetic Changes in Prostate Cancer Stroma. Appl ID 1044458	1/03/2013	30/06/2016	N	N	\$597,987.00
2013-14	Monash University	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): An inhalable dendrimer-based delivery platform for the targeted treatment of primary and secondary lung cancers. App1070184	23/04/2014	30/07/2017	N	N	\$452,383.00
2012-13	Monash University	Investigating symptoms of lung cancer - a guide for general practitioners	1/02/2011	31/12/2016	N		\$975,282.00
2012-13	Monash University	Support for Cancer Clinical Trials - ANZCHOG	25/06/2010	31/08/2013	N		\$1,509,780.20
2012-13	Monash University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Determining the causes of observed variation in survival after diagnosis of prostate cancer	30/05/2011	30/09/2014	N		\$627,607.20
2012-13	Monash University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Defining Epigenetic Changes in Prostate Cancer Stroma	31/03/2013	30/06/2016	N		\$597,987.00
2011-12	Monash University	Evidence based guidance and associated educational and support materials for General Practitioners to support timely and early referral of people who have or may have lung cancer	7/03/2011	30/06/2013	N		\$985,182.00
2011-12	Monash University	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Determining the causes of observed variation in survival after diagnosis of prostate cancer	30/05/2011	30/06/2014	N		\$627,607.20
2011-12	Monash University	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Pilot of population-based prostate cancer clinical registry	26/02/2010	14/03/2013	N		\$217,387.50
2018-19	Monash University	Capacity building support to the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,410,000.00
2018-19	Monash University	2019 Supporting People with Cancer Round 11	14/03/2019	30/05/2022	N	N	\$120,000.00

2019-20	Monash University	2019 Supporting People with Cancer Round 11: Integrated Management of Post Remission Leukaemia to Optimise longevity and Enhance Quality of Life (IMPROVE). This project aims to improve post-remission care for patients treated with acute leukemia.	14/03/2019	30/05/2022	N	N	\$120,000
2019-20	Monash University	Capacity building support to the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,500,000
2019-20	Monash University	Capacity building support to the Melanoma and Skin Cancer Trials (MASC; formerly ANZMTG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,500,000
2019-20	Monash University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) international 2019: Checkpoint receptors expressed by dendritic cells- do they play a role in immunotherapies?. APPID: 20-0300-O'Keefe	01/02/2020	01/02/2023	N	N	\$241,027
2019-20	Monash University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Translating Colorectal Cancer Organoids into Patient Care APPID: 1145907-Abud	16/04/2018	15/07/2021	N	N	\$597,557
2019-20	Monash University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2014: Pain Free TRUS B: A placebo-controlled, randomised trial of methoxyflurane to reduce the discomfort of prostate biopsy. APPID: 1079794-Davis	20/06/2015	30/09/2020	N	N	\$354,764
2019-20	Monash University	Investing in medical Research - fighting childhood cancer: LGG Avastin study	27/10/2017	30/11/2021	N	N	\$507,419
2019-20	Monash University	Investing in medical Research - fighting childhood cancer: AIM BRAIN trial	27/10/2017	30/06/2021	N	N	\$1,742,898
2016-17	Monash University/Australian and New Zealand Children's Haematology/Oncology Group (through Monash University)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2018	N	NA	\$2,299,173.00
2013-14	National Breast Cancer Foundation	Establish a national cohort of Australian women recruited through BreastScreen Australia Services, for the purposes of developing a national database and resource, which can support a wide range of breast cancer studies to improve detection and treatment	30/06/2009	31/03/2015	N	N	\$2,749,823.47
2012-13	National Breast Cancer Foundation	Establish a national cohort of Australian women recruited through BreastScreen Australia Services, for the purposes of developing a national database and resource, which can support a wide range of breast cancer studies to improve detection and treatment	30/06/2009	30/09/2014	N		\$2,749,823.47
2011-12	National Breast Cancer Foundation	Establish a national cohort of Australian women recruited through BreastScreen Australia Services, for the purposes of developing a national database and resource, which can support a wide range of breast cancer studies to improve detection and treatment	30/06/2009	30/09/2014	N		\$2,749,823.47
2012-13	National Breast Cancer Foundation	Developing a National Database and Resource which can Support a wide range of Breast Cancer Studies to Improve Detection and Treatment	30/06/2009	30/06/2014	N		\$2,749,823.47
2012-13	National Health and Medical Research Centre Clinical Trials Centre	Technical Services of a Genomic Cancer Clinical Trial Initiative (GCCTI) to develop mutation-specific cancer clinical trials protocols	25/06/2013	1/08/2016	N		\$1,350,000.00
2016-17	Newcastle Innovation Limited/Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2018	N	NA	\$2,529,938.00
2013-14	Nexus Australasia Pty Ltd	Technical consultant to support the implementation of the Lung Cancer	11/02/2014	31/10/2014	N	N	\$110,000.00
2013-14	NGA.NET Pty Ltd	Implement and support a E-Recruit system for Cancer Australia	21/06/2013	20/06/2016	N	N	\$163,812.00
2012-13	NGA.NET Pty Ltd	Implement and support a E-Recruit system for Cancer Australia	21/06/2013	20/06/2016	N		\$163,812.00
2011-12	North Coast Cancer Institute, Coffs Harbour	Implement a portfolio of active industry-independent trials undertaken by Australia's National Multi-site Collaborative National Cancer Clinical Trials Groups, thereby increasing access to clinical trials in regional Australia	1/02/2009	31/08/2011	N		\$237,786.80
2011-12	North Coast Cancer Institute, Port Macquarie	To implement a portfolio of active industry-independent trials undertaken by Australia's National Multi-site Collaborative National Cancer Clinical Trials Groups, thereby increasing access to clinical trials in regional Australia	1/02/2009	31/08/2011	N		\$328,565.53
2017-18	North Metropolitan Health Service	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/03/2017	30/06/2020	N	N	\$112,462.00
2016-17	North Metropolitan Health Service	Supporting people with cancer Grant initiative: Adolescent and Young Adult (AYA) Life Now Group Exercise Program	30/03/2017	30/06/2020	N	NA	\$112,462.00
2019-20	North Metropolitan Health Service	Supporting people with cancer Grant initiative: Adolescent and Young Adult (AYA) Life Now Group Exercise Program	30/03/2017	30/06/2021	N	N	\$112,462
2011-12	Northern Territory Department of Health and Community Services	The continuation of Cancer Service Networks National Demonstration Program (CanNET) in the Northern Territory	10/02/2010	30/06/2012	N		\$849,695.00
2017-18	Peter MacCallum Cancer Centre	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/05/2018	30/03/2021	N	N	\$128,700.00
2016-17	Peter MacCallum Cancer Centre	Cancer Australia's Supporting people with cancer grant initiative will continue to improve the coordination, accessibility and development of quality cancer support networks to better support people affected by cancer.	30/03/2016	30/03/2016	N	NA	\$159,500.00

2012-13	Peter MacCallum Cancer Centre	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: Randomised phase III trial to assess response adapted therapy using PET in newly diagnosed advanced Hodgkin lymphoma	1/02/2010	31/10/2013	N		\$113,333.33
2011-12	Peter MacCallum Cancer Centre	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Randomised phase III trial to assess response adapted therapy using PET in newly diagnosed advanced Hodgkin Lymphoma	22/01/2010	1/02/2013	N		\$124,666.67
2019-20	Peter MacCallum Cancer Centre	Supporting People with Cancer Grant Initiative: Development of a co-designed, online, supportive care resources for older adults affected by cancer. The "Older and Wiser" project.	01/05/2018	30/03/2021	N	N	\$128,700
2015-16	PETER MACCALLUM CANCER INSTITUTE T/A PETER MACCALLUM CANCER CENTRE	SUPPORTING PEOPLE WITH CANCER (SPWC) 2016: IMPROVING INFORMATION PROVISION AND SUPPORT FOR UNDERSERVED CANCER SURVIVORS. DEVELOP CULTURALLY APPROPRIATE RESOURCES THAT MEET THE UNMET INFORMATION NEEDS OF CANCER SURVIVORS FROM DISADVANTAGED GROUPS, INCLUDING CULTURALLY AND LINGUISTICALLY DIVERSE BACKGROUNDS AND THOSE WITH LIMITED LITERACY.	30/03/2016	30/07/2019	N		\$159,500.00
2015-16	PRIMARY CARE COLLABORATIVE CLINICAL TRIALS GROUP (THROUGH UNIVERSITY OF MELBOURNE)	SUPPORT FOR CANCER CLINICAL TRIALS PROGRAM	1/07/2013	31/08/2016	N		\$1,379,786.00
2014-15	Primary Care Collaborative Clinical trials Group (through University of Melbourne)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,379,786.00
2013-14	Primary Care Collaborative Clinical trials Group (through University of Melbourne)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N	N	\$1,379,786.00
2012-13	Primary Care Collaborative Clinical trials Group (through University of Melbourne)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,379,786.00
2017-18	Primary Care Collaborative Cancer Clinical Trials Group (through University of Melbourne)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/06/2018	1/09/2021	N	N	\$1,500,000.00
2017-18	Primary Care Collaborative Cancer Clinical Trials Group (through University of Melbourne)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	25/06/2018	31/08/2018	N	N	\$2,299,786.00
2012-13	Prince Charles Hospital	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Individualising treatment for mesothelioma	13/03/2013	31/07/2013	N		\$384,450.00
2011-12	Prince Charles Hospital	Individualising treatment for mesothelioma	13/01/2009	28/02/2012	N		\$384,450.00
2017-18	Prince of Wales Hospital	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2017	29/09/2020	N	N	\$221,534.04
2016-17	Prince of Wales Hospital	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma: the CODEL trial: ID1130584	30/06/2017	29/09/2020	N	NA	\$221,534.04
2013-14	Prostate Cancer Foundation Australia	Funding Agreement for PCFA - Supporting men with Prostate cancer	1/09/2011	30/06/2015	N	N	\$4,279,000.00
2012-13	Prostate Cancer Foundation Australia	Funding Agreement for PCFA - Supporting men with Prostate cancer	1/09/2011	30/06/2014	N		\$3,970,000.00
2011-12	Prostate Cancer Foundation Australia	Funding Agreement for PCFA - Supporting men with Prostate cancer	1/09/2011	30/06/2014	N		\$3,970,000.00
2017-18	Psycho-oncology Co-operative Research Group (through University of Sydney)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/06/2018	1/09/2021	N	N	\$1,477,995.00
2017-18	Psycho-oncology Co-operative Research Group (through University of Sydney)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	25/06/2018	31/08/2018	N	N	\$2,298,065.00
2015-16	PSYCHO-ONCOLOGY CO-OPERATIVE RESEARCH GROUP (THROUGH UNIVERSITY OF SYDNEY)	SUPPORT FOR CANCER CLINICAL TRIALS PROGRAM	1/07/2013	31/08/2016	N		\$1,378,065.00
2016-17	Psycho-oncology Co-operative Research Group (through University of Sydney)	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2018	N	NA	\$2,298,065.00
2014-15	Psycho-oncology Co-operative Research Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,378,065.00
2013-14	Psycho-oncology Co-operative Research Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N	N	\$1,378,065.00
2012-13	Psycho-oncology Co-operative Research Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,378,065.00
2012-13	Psycho-oncology Co-operative Research Group (through University of Sydney)	Support for Cancer Clinical Trials Program	25/06/2010	31/08/2013	N		\$1,581,591.83
2016-17	QIMR Berghofer Medical Research Institute	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Dnmt3a loss contributes to disease progression in myeloproliferative neoplasm: ID1124096	17/04/2017	16/07/2019	N	NA	\$100,000.00
2013-14	Queen Elizabeth Hospital	Procurement of evaluation data. Shared follow-up care for women with early breast cancer 2013-2015	27/06/2013	15/09/2015	N	N	\$180,000.00
2011-12	Queensland Health	Cancer care coordination for Indigenous people residing in Far North Queensland	25/05/2011	30/06/2012	N		\$389,400.00

2011-12	Queensland Health	Support for Cancer Clinical Trials	25/06/2010	31/08/2011	N		\$130,987.01
2013-14	Queensland Health (Metro North Hospital and Health Service - Royal Brisbane and Women's Hospital)	Procurement of evaluation data: Shared follow-up care for women with early breast cancer 2013-2015	28/06/2013	15/09/2015	N	N	\$140,000.00
2013-14	Queensland Health (Metro North Hospital and Health Service)	Lung cancer service delivery to demonstrate best practice approaches to lung cancer treatment and care.	25/06/2014	30/06/2015	N	N	\$125,000.00
2017-18	Queensland Health (Princess Alexandra Hospital Metro South District)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	28/02/2014	28/08/2019	N	N	\$335,000.00
2017-18	Queensland Health (Princess Alexandra Hospital Metro South District)	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/05/2012	31/07/2018	N	N	\$297,468.00
2013-14	Queensland Health (Princess Alexandra Hospital Metro South District)	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: A randomised Phase III trial of High Dose Palliative Radiotherapy (HDPRT) versus concurrent Chemotherapy and HDPRT (C-HDPRT) in patients with Good performance Status. Locally Advanced/Small Volume Metastatic Non-small Cell Lung Cancer not suitable for Radical Chemo-therapy	21/02/2012	30/07/2015	N	N	\$327,214.80
2012-13	Queensland Health (Princess Alexandra Hospital Metro South District)	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: A randomised Phase III trial of High Dose Palliative Radiotherapy (HDPRT) versus concurrent Chemotherapy and HDPRT (C-HDPRT) in patients with Good performance Status. Locally Advanced/Small Volume Metastatic Non-small Cell Lung Cancer not suitable for Radical Chemo-therapy	21/02/2012	30/07/2015	N		\$327,214.80
2012-13	Queensland Health (Princess Alexandra Hospital Metro South District)	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Phase II Efficacy Study of Chemo-Radiotherapy in PET Staged II-III Merkel Cell Carcinoma of the Skin	5/01/2009	30/04/2015	N		\$101,750.00
2015-16	QUEENSLAND HEALTH (PRINCESS ALEXANDRA HOSPITAL METRO SOUTH HOSPITAL AND HEALTH SERVICE)	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2008: PHASE II EFFICACY STUDY OF CHEMO-RADIOTHERAPY IN PET STAGED II-III MERKEL CELL CARCINOMA OF THE SKIN: APP ID 551200	31/01/2009	31/10/2016	N		\$101,750.00
2015-16	QUEENSLAND HEALTH (PRINCESS ALEXANDRA HOSPITAL METRO SOUTH HOSPITAL AND HEALTH SERVICE)	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2011: A RANDOMISED PHASE III TRIAL OF HIGH DOSE PALLIATIVE RADIOOTHERAPY (HDPRT) VERSUS CONCURRENT CHEMOTHERAPY AND HDPRT (C-HDPRT) IN PATIENTS WITH GOOD PERFORMANCE STATUS. LOCALLY ADVANCED/SMALL VOLUME METASTATIC NON-SMALL CELL LUNG CANCER NOT SUITABLE FOR RADICAL CHEMO-THERAPY. APP1030265	1/05/2012	31/07/2018	N		\$327,214.80
2015-16	QUEENSLAND HEALTH (PRINCESS ALEXANDRA HOSPITAL METRO SOUTH HOSPITAL AND HEALTH SERVICE)	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): A RANDOMISED TRIAL OF POSTOPERATIVE RADIATION THERAPY FOLLOWING WIDE EXCISION OF NEUROTROPIC MELANOMA OF THE HEAD AND NECK. APP ID: 1060687	28/02/2014	27/05/2017	N		\$335,000.00
2016-17	Queensland Health (Princess Alexandra Hospital Metro South Hospital and Health Service)	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: A randomised Phase III trial of High Dose Palliative Radiotherapy (HDPRT) versus concurrent Chemotherapy and HDPRT (C-HDPRT) in patients with Good performance Status. Locally Advanced/Small Volume Metastatic Non-small Cell Lung Cancer not suitable for Radical Chemo-therapy. App1030265	1/05/2012	31/07/2018	N	NA	\$327,214.80
2016-17	Queensland Health (Princess Alexandra Hospital Metro South Hospital and Health Service)	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): A Randomised Trial of Postoperative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck.App1060687	28/02/2014	27/05/2018	N	NA	\$335,000.00
2014-15	Queensland Health (Princess Alexandra Hospital Metro South Hospital and Health Service)	Priority Driven Collaborative Cancer Research Scheme 2008: Phase II Efficacy Study of Chemo-Radiotherapy in PET Staged II-III Merkel Cell Carcinoma of the Skin	6/01/2009	31/10/2016	N		\$101,750.00
2014-15	Queensland Health (Princess Alexandra Hospital Metro South Hospital and Health Service)	Priority Driven Collaborative Cancer Research Scheme 2011: A randomised Phase III trial of High Dose Palliative Radiotherapy versus concurrent Chemotherapy and High Dose Palliative Radiotherapy in patients with Good performance Status. Locally Advanced/Small Volume Metastatic Non-small Cell Lung Cancer not suitable for Radical Chemo-therapy	21/02/2012	31/07/2018	N		\$327,214.80
2014-15	Queensland Health (Princess Alexandra Hospital Metro South Hospital and Health Service)	2013 Priority-driven Collaborative Cancer Research Scheme: A Randomised Trial of Postoperative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck.	20/02/2014	27/05/2017	N		\$335,000.00
2013-14	Queensland Health (Princess Alexandra Hospital)	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): A Randomised Trial of Postoperative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck. App1060687	16/06/2014	27/05/2017	N	N	\$335,000.00
2011-12	Queensland Health (Princess Alexandra Hospital, Metro South District)	2011 - Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - A randomised Phase III trial of High Dose Palliative Radiotherapy (HDPRT) versus concurrent Chemotherapy and HDPRT (C-HDPRT) in patients with Good performance Status. Locally Advanced/Small Volume Metastatic Non-small Cell Lung Cancer not suitable for Radical Chemo-therapy	21/02/2012	30/04/2015	N		\$327,214.80

2011-12	Queensland Health (Princess Alexandra Hospital, Metro South District)	Phase II Efficacy Study of Chemo-Radiotherapy in PET Staged II-III Merkel Cell Carcinoma of the Skin	5/01/2009	31/01/2015	N		\$101,750.00
2017-18	Queensland Institute of Medical Research	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	17/04/2017	16/07/2019	N	N	\$100,000.00
2013-14	Queensland Institute of Medical Research	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Development of a model to classify mismatch repair gene sequence variants of uncertain clinical significance	16/09/2013	31/05/2015	N	N	\$660,000.00
2013-14	Queensland Institute of Medical Research	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Identifying markers of risk and outcome in ovarian and breast cancer via efficient of DNA methylation in peripheral blood	15/02/2011	31/03/2015	N	N	\$191,213.00
2012-13	Queensland Institute of Medical Research	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Development of a model to classify mismatch repair gene sequence variants of uncertain clinical significance	11/02/2011	31/05/2014	N		\$660,000.00
2012-13	Queensland Institute of Medical Research	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Improving Outcomes for Women with Endometrial Cancer: Follow-up, survival and quality of life	21/01/2009	31/03/2014	N		\$656,466.80
2012-13	Queensland Institute of Medical Research	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Identifying markers of risk and outcome in ovarian and breast cancer via efficient of DNA methylation in peripheral blood	15/02/2011	31/05/2014	N		\$191,213.00
2011-12	Queensland Institute of Medical Research	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Development of a model to classify mismatch repair gene sequence variants of uncertain clinical significance	11/02/2011	28/02/2014	N		\$660,000.00
2011-12	Queensland Institute of Medical Research	2008 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Improving Outcomes for Women with Endometrial Cancer: Follow-up, survival and quality of life	21/01/2009	30/06/2012	N		\$656,466.80
2011-12	Queensland Institute of Medical Research	Response to chemotherapy in ovarian cancer	20/01/2009	30/04/2012	N		\$625,625.00
2011-12	Queensland Institute of Medical Research	Towards new screening tests for oesophageal adenocarcinoma	20/01/2009	30/06/2012	N		\$512,325.00
2011-12	Queensland Institute of Medical Research	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Identifying markers of risk and outcome in ovarian and breast cancer via efficient of DNA methylation in peripheral blood	15/02/2011	28/02/2014	N		\$191,213.00
2017-18	Queensland University of Technology	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/06/2018	28/09/2021	N	N	\$599,756.00
2017-18	Queensland University of Technology	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/05/2015	30/07/2019	N	N	\$600,000.00
2015-16	QUEENSLAND UNIVERSITY OF TECHNOLOGY	2014 PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): IDENTIFICATION OF HNF1B DOWNSTREAM TARGETS AS NOVEL CANCER THERAPEUTIC TARGETS AND BIOMARKERS. APP. 1086820	30/06/2015	30/09/2017	N		\$100,000.00
2015-16	QUEENSLAND UNIVERSITY OF TECHNOLOGY	2014 PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): EVALUATING COMBINATION THERAPIES IN FGFR2MUTANT EC CELL LINES AND PATIENT-DERIVED XENOGRAFT MODELS.. APP. 1087165	1/05/2015	30/07/2018	N		\$600,000.00
2016-17	Queensland University of Technology	2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Evaluating combination therapies in FGFR2mutant EC cell lines and patient-derived xenograft models.. App. 1087165	1/05/2015	30/07/2018	N	NA	\$600,000.00
2016-17	Queensland University of Technology	2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Identification of HNF1B downstream targets as novel cancer therapeutic targets and biomarkers. App. 1086830	30/06/2015	31/03/2018	N	NA	\$100,000.00
2014-15	Queensland University of Technology	2014 Priority Driven Collaborative Cancer Research Scheme: Identification of HNF1B downstream targets as novel cancer therapeutic targets and biomarkers.	13/04/2015	30/09/2017	N		\$100,000.00
2014-15	Queensland University of Technology	2014 Priority Driven Collaborative Cancer Research Scheme: Evaluating combination therapies in FGFR2mutant EC cell lines and patient-derived xenograft models.	29/04/2015	30/07/2018	N		\$600,000.00
2013-14	Queensland University of Technology	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Mirena ± Weight Loss to treat early Endometrial Cancer: (MAXWEL Trial). Appl ID 1044900	8/03/2013	30/06/2016	N	N	\$600,000.00
2012-13	Queensland University of Technology	Managing, developing and maintaining the National Cancer Nursing Education Project (Phase III) and the interactive training module for health professionals to address the psychosexual care for women affected by gynaecological cancers (Phase II)	22/02/2011	31/12/2013	N		\$932,828.60

2012-13	Queensland University of Technology	Priority Driven Collaborative Cancer Research Scheme (PdCCRS) 2010: Skin cancer prevention & early detection for Generation Y	30/06/2011	30/09/2013	N		\$343,776.40
2012-13	Queensland University of Technology	Priority Driven Collaborative Cancer Research Scheme (PdCCRS) 2012: Mirena ± Weight Loss to treat early Endometrial Cancer: (MAXWEL Trial). Appl ID 1044900	1/04/2013	30/06/2016	N		\$600,000.00
2011-12	Queensland University of Technology	Managing, developing and maintaining the National Cancer Nursing Education Project (Phase III) and the interactive training module for health professionals to address the psychosexual care for women affected by gynaecological cancers (Phase II)	22/02/2011	30/11/2012	N		\$932,828.60
2011-12	Queensland University of Technology	Managing, developing and maintaining the National Cancer Nursing Education Project (Phase III) and the interactive training module for health professionals to address the psychosexual care for women affected by gynaecological cancers (phase II)	22/02/2011	30/11/2012	N		\$932,828.60
2011-12	Queensland University of Technology	Skin cancer prevention & early detection for Generation Y	30/06/2011	30/06/2013	N		\$343,776.40
2018-19	Queensland University of Technology	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Development of a translational bioengineered microenvironment model to advance pre-clinical acute myeloid leukaemia research AppID: 1159637 - BRAY	30/06/2019	30/09/2021	N		\$133,017.00
2019-20	Queensland University of Technology	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Humanized rat models - the next frontier in pre-clinical osteosarcoma research. APPID: 1181919-McGovern	01/01/2021	31/03/2023	N	N	\$131,710
2019-20	Queensland University of Technology	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Development of a translational bioengineered microenvironment model to advance pre-clinical acute myeloid leukaemia research AppID: 1159637 - BRAY	30/06/2019	29/09/2021	N	N	\$133,017
2019-20	Queensland University of Technology	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Circulating Tumour Cells: Clinical Application in Head and Neck Cancers APPID: 1145657-Punyadeera	29/06/2018	28/09/2021	N	N	\$599,756
2015-16	RARE CANCERS AUSTRALIA LTD	SUPPORTING PEOPLE WITH CANCER (SPWC) -2015 DEVELOP A ONE-STOP-SHOP FOR PEOPLE AFFECTED BY RARE CANCERS, INCLUDING AN ONLINE DIRECTORY OF MORE THAN 200 RARE AND LESS COMMON CANCER TYPES AND A REGISTER OF CANCER SPECIALISTS AND MULTIDISCIPLINARY TEAMS WITH EXPERTISE AND INTEREST IN RARE CANCERS.	4/06/2015	30/06/2018	N		\$132,000.00
2016-17	Rare Cancers Australia Ltd	SPWC -Develop a one-stop-shop for people affected by rare cancers, including an online directory of more than 200 rare and less common cancer types and a register of cancer specialists and multidisciplinary teams with expertise and interest in rare cancers.	4/06/2015	30/06/2018	N	NA	\$132,000.00
2014-15	Rare Cancers Australia Ltd	Supporting People with Cancer -Develop a one-stop-shop for people affected by rare cancers, including an online directory of more than 200 rare and less common cancer types and a register of cancer specialists and multidisciplinary teams with expertise and interest in rare cancers.	4/06/2015	30/06/2018	N		\$132,000.00
2012-13	Roex Management	Appointed personnel to chair services for CA Audit Committee	27/09/2007	27/09/2014	N		\$176,000.00
2013-14	Roex Management Pty Ltd	Chair services for CA Audit Committee	27/09/2007	27/09/2014	N	N	\$176,000.00
2011-12	Rural Health Education Foundation	To increase rural & regional health professionals' knowledge & understanding of gynaecological cancers.	25/10/2010	30/08/2011	N		\$332,660.00
2012-13	Secretariat Australia	National Secretariat Services for the Multi-site Collaborative National Cancer Clinical Trials Groups	28/06/2011	30/09/2013	N		\$437,602.00
2011-12	Secretariat Australia	National Secretariat Services for the Multi-site Collaborative National Cancer Clinical Trials Groups	1/07/2010	14/08/2011	N		\$256,630.00
2011-12	Secretariat Australia	National Secretariat Services for the Multi-site Collaborative National Cancer Clinical Trials Groups	28/06/2011	30/09/2013	N		\$437,602.00
2011-12	Siggins Miller	Establishment of a National Coordination, Evaluation and Support Service for the Gynaecological Workforce project	29/06/2009	31/07/2011	N		\$317,825.00
2011-12	Siggins Miller	Deed of variation in relation to contract: National Evaluation and Support services CANNET Projects 2009-12	23/11/2009	31/08/2012	N		\$551,000.00
2011-12	South Australian Department of Health	CanNET	10/02/2010	30/06/2012	N		\$1,474,911.00
2013-14	South Australian Health and Medical Research Institute Ltd	Provision of professional technical epidemiological and data services.	1/07/2014	30/06/2015	N	N	\$217,400.04
2013-14	State of Queensland through Queensland Health via The Princess Alexandra Hospital Metro South District	Priority Driven Collaborative Cancer Research Scheme (PdCCRS) 2008: Phase II Efficacy Study of Chemo-Radiotherapy in PET Staged II-III Merkel Cell Carcinoma of the Skin	11/05/2012	30/04/2015	N	N	\$101,750.00
2018-19	Swinburne University	2019 Supporting People with Cancer Round 11	26/02/2019	30/05/2022	N	N	\$120,000.00
2019-20	Swinburne University	2019 Supporting People with Cancer Round 11: Australian Carers Talk: An online cancer support resource for carers designed by carers. This Project will deliver an online resource created by carers for carers, integrated into Cancer Council Australia's new national website.	26/02/2019	30/05/2022	N	N	\$120,000

2017-18	Sydney Children's Hospital	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	14/04/2017	13/07/2020	N	N	\$200,000.00
2016-17	Sydney Children's Hospital	Priority Driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Synthetic retinoid therapy for Diffuse Intrinsic Pontine Gliomas: ID1126580	14/04/2017	13/07/2020	N	NA	\$200,000.00
2013-14	Sydney Local Health District	Lung cancer service delivery to demonstrate best practice approaches to lung cancer treatment and care.	6/06/2014	30/06/2015	N	N	\$125,000.00
2011-12	Tasmanian Department of Health and Human Services	To implement a portfolio of active industry-independent trials undertaken by Australia's National Multi-site Collaborative National Cancer Clinical Trials Groups, thereby increasing access to clinical trials in regional Australia	1/02/2009	31/08/2011	N		\$281,328.05
2011-12	Tasmanian Department of Health and Human Services	The continuation of Cancer Service Networks National Demonstration Program (CanNET) in Tasmania	10/02/2010	28/05/2012	N		\$394,800.00
2013-14	Tasmanian Health Organisation - South	Lung cancer service delivery to demonstrate best practice approaches to lung cancer treatment and care.	30/06/2014	30/06/2015	N	N	\$125,000.00
2012-13	Telstra	Rural Women Project	20/05/2011	29/07/2014	N		\$284,700.00
2012-13	Telstra	Provision of 2 NCS links (Canberra and Melbourne office) for internet services.	19/02/2012	18/02/2014	N		\$102,584.86
2011-12	Telstra	Rural Women Project	20/05/2011	19/05/2013	N		\$214,500.00
2011-12	Telstra	Provision of 2 NCS links (Canberra and Melbourne office) for internet services.	19/02/2012	18/02/2014	N		\$102,584.86
2013-14	Telstra Corporation Limited	For Rural Women Project	20/05/2011	29/07/2014	N	N	\$265,200.00
2019-20	The Kids Cancer Project	Investing in Medical Research – fighting childhood cancer: Support for the Non-Government sector to raise awareness for childhood cancer - Awareness campaign led by The Kid's Cancer Project	31/08/2017	31/08/2020	N	N	\$214,500
2017-18	The Kid's Cancer Project	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	31/08/2017	31/08/2020	N	N	\$214,500.00
2019-20	The University of Newcastle	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Obesity epidemic fuelling the surge of endometrial cancers: Elucidating the role and targeting of molecular signals involved in fat and endometrial cancer cross-talk. APPID: 1187542-Tanwar	31/03/2020	28/05/2023	N	N	\$600,000
2019-20	The University of Sydney	2019 Supporting People with Cancer Round 11 - Aboriginal people with cancer to access evidence based care: developing a manual and training package in use for workers in primary care to support cancer care	30/05/2019	30/05/2022	N	N	\$120,000
2019-20	The University of Sydney	Capacity building support to the Australian Gastro-intestinal Trials Group (AGITG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,500,000
2019-20	The University of Sydney	Capacity building support to the Australasian Lung Cancer Trials Group (ALTG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,500,000
2019-20	The University of Sydney	Capacity building support to the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,500,000
2019-20	The University of Sydney	Capacity building support to the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,500,000
2019-20	The University of Sydney	Capacity building support to the Cooperative Trials Group for Neuro-Oncology (COGNO) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,500,000
2019-20	The University of Sydney	Capacity building support to the Psycho-oncology Co-operative Research Group (PoCoG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,477,995
2019-20	The University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Personalised targeted therapy for adolescent and young adult medulloblastoma patients AppID: 1165910-HOVEY	30/06/2019	29/09/2022	N	N	\$167,169
2019-20	The University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: P3BEP Trial: Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours: An Australian-Led, International Randomised Trial. AppID: 1159837-GRIMISON	30/06/2019	29/09/2022	N	N	\$600,000
2019-20	The University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: The ECHO trial: Exercise during Chemotherapy for Ovarian cancer AppID: 1158566-HAYES	14/05/2019	13/08/2022	N	N	\$597,443
2019-20	The University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Improving tumour targeting and delineation in lung cancer radiotherapy AppID: 1161748-O'Brien	30/06/2019	29/09/2023	N	N	\$600,000

2019-20	The University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Empowering the clinician-patient-carer TRIO: RCT of novel online education modules to facilitate effective family carer involvement in oncology APPID: 1146383-Juraskova	19/03/2018	18/03/2023	N	N	\$296,601
2017-18	Trans Tasman Radiation Oncology Group	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/06/2018	1/09/2021	N	N	\$1,650,000.00
2017-18	Trans Tasman Radiation Oncology Group	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	25/06/2018	31/08/2018	N	N	\$2,530,000.00
2016-17	Trans Tasman Radiation Oncology Group	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2018	N	NA	\$2,530,000.00
2018-19	Trans Tasman Radiation Oncology Group	Capacity building support to the Trans Tasman Radiation Oncology Group (TROG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,650,000.00
2018-19	Trans Tasman Radiation Oncology Group	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Novel Integration of New prostate radiation schedules with adjuvant Androgen deprivation (NINJA) AppID: 1158455-MARTIN	30/06/2019	29/09/2022	N	N	\$600,000.00
2019-20	Trans Tasman Radiation Oncology Group	Capacity building support to the Trans Tasman Radiation Oncology Group (TROG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,650,000
2019-20	Trans Tasman Radiation Oncology Group	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Novel Integration of New prostate radiation schedules with adjuvant Androgen deprivation (NINJA) AppID: 1158455-MARTIN	30/06/2019	29/09/2022	N	N	\$600,000
2013-14	Trans Tasman Radiation Oncology Group Limited	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: A randomised comparison of anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy	25/06/2010	30/09/2014	N	N	\$660,000.00
2012-13	Trans Tasman Radiation Oncology Group Limited	Support for Cancer Clinical Trials	25/06/2010	31/08/2013	N		\$1,549,297.20
2012-13	Trans Tasman Radiation Oncology Group Limited	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: A randomised comparison of anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy	25/06/2010	30/06/2013	N		\$660,000.00
2012-13	Trans Tasman Radiation Oncology Group Limited	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: Phase II Trial of integrated preoperative RT/chemo with oxaliplatin, 5-FU and FA in locally advanced rectal cancer	23/02/2010	30/09/2013	N		\$118,250.00
2012-13	Trans Tasman Radiation Oncology Group Limited	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,518,000.00
2011-12	Trans Tasman Radiation Oncology Group Limited	Support for Cancer Clinical Trials	25/06/2010	30/06/2013	N		\$1,549,297.20
2011-12	Trans Tasman Radiation Oncology Group Limited	A randomised comparison of anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy	25/06/2010	30/06/2013	N		\$660,000.00
2011-12	Trans Tasman Radiation Oncology Group Limited	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Phase II Trial of integrated preoperative RT/chemo with oxaliplatin, 5-FU and FA in locally advanced rectal cancer	12/02/2010	30/06/2013	N		\$118,250.00
2015-16	TRANSTASMAN RADIATION ONCOLOGY GROUP	SUPPORT FOR CANCER CLINICAL TRIALS PROGRAM	1/07/2013	31/08/2016	N		\$1,518,000.00
2014-15	TransTasman Radiation Oncology Group	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N		\$1,518,000.00
2013-14	TransTasman Radiation Oncology Group	Support for Cancer Clinical Trials Program	25/06/2013	31/08/2016	N	N	\$1,518,000.00
2018-19	University of New South Wales	2019 Supporting People with Cancer Round 11	21/05/2019	30/05/2022	N		\$119,660.25
2019-20	University of New South Wales	2019 Supporting People with Cancer Round 11: Co-designing patient engagement strategies to enhance safety in cancer services for culturally and linguistically diverse (CALD) people	21/05/2019	30/05/2022			\$119,660
2017-18	University of Adelaide	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	16/04/2018	29/06/2021	N	N	\$596,409.00
2017-18	University of Adelaide	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/04/2015	1/07/2018	N	N	\$553,483.00
2017-18	University of Adelaide	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/05/2013	31/07/2019	N	N	\$360,977.00
2015-16	UNIVERSITY OF ADELAIDE	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2012: A PHARMACODYNAMIC STUDY OF THE HEAT SHOCK PROTEIN 90 (HSP90) INHIBITOR, AUY922, IN HIGH-RISK, LOCALISED PROSTATE CANCER. APPL ID 1050880.	1/06/2013	31/07/2018	N		\$360,977.00
2015-16	UNIVERSITY OF ADELAIDE	2014 PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): MOLECULAR HALLMARKS OF HEAT SHOCK PROTEIN 90 INHIBITION IN PROSTATE CANCER. APP. 1085471	1/04/2015	1/07/2018	N		\$553,483.00

2016-17	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: A pharmacodynamic study of the heat shock protein 90 (Hsp90) inhibitor, AUY922, in high-risk, localised prostate cancer. Appl ID 1050880.	1/06/2013	31/07/2018	N	NA	\$360,977.00
2016-17	University of Adelaide	2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Molecular hallmarks of heat shock protein 90 inhibition in prostate cancer. App. 1085471	1/04/2015	1/07/2018	N	NA	\$553,483.00
2014-15	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme 2011: Androgen receptor action in the prostate cancer microenvironment	20/03/2012	31/03/2016	N		\$316,571.20
2014-15	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme 2012: A pharmacodynamic study of the heat shock protein 90 (Hsp90) inhibitor, AUY922, in high-risk, localised prostate cancer.	11/02/2013	31/07/2017	N		\$360,977.00
2014-15	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme 2012: Mechanism and targeting of castration-resistant prostate cancer.	11/02/2013	30/06/2016	N		\$270,569.00
2014-15	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme 2012: Targeting the androgen receptor in triple negative breast cancer.	11/02/2013	30/06/2016	N		\$196,474.70
2014-15	University of Adelaide	2014 Priority Driven Collaborative Cancer Research Scheme: Molecular hallmarks of heat shock protein 90 inhibition in prostate cancer.	1/04/2015	1/07/2018	N		\$553,483.00
2013-14	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Androgen receptor action in the prostate cancer microenvironment	20/03/2012	31/08/2015	N	N	\$316,571.20
2013-14	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Is elevated N-cadherin expression a poor prognostic indicator in multiple myeloma patients	18/03/2012	17/06/2015	N	N	\$290,766.30
2013-14	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: A pharmacodynamic study of the heat shock protein 90 (Hsp90) inhibitor, AUY922, in high-risk, localised prostate cancer. Appl ID 1050880.	11/02/2013	31/07/2016	N	N	\$360,977.00
2013-14	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Mechanism and targeting of castration-resistant prostate cancer. Appl ID 1043482.	11/02/2013	30/06/2016	N	N	\$270,569.00
2013-14	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Targeting the androgen receptor in triple negative breast cancer. Appl ID 1043497.	11/02/2013	30/06/2016	N	N	\$196,474.70
2012-13	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: A novel approach to predict metastatic potential of prostate cancer at diagnosis	1/03/2011	30/06/2014	N		\$650,905.20
2012-13	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: A combinatorial approach targeting androgen signalling for treatment of prostate cancer	12/03/2010	30/06/2013	N		\$321,028.95
2012-13	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Androgen receptor action in the prostate cancer microenvironment	20/03/2012	31/08/2015	N		\$316,571.20
2012-13	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: The role of CD123 in MDSA and AML	28/02/2011	13/06/2014	N		\$316,276.40
2012-13	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Is elevated N-cadherin expression a poor prognostic indicator in multiple myeloma patients	20/03/2012	17/06/2016	N		\$290,766.30
2012-13	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: A pharmacodynamic study of the heat shock protein 90 (Hsp90) inhibitor, AUY922, in high-risk, localised prostate cancer. Appl ID 1050880.	1/05/2013	31/07/2016	N		\$360,977.00
2012-13	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Mechanism and targeting of castration-resistant prostate cancer. Appl ID 1043482.	1/04/2013	30/06/2016	N		\$270,569.00
2012-13	University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Targeting the androgen receptor in triple negative breast cancer. Appl ID 1043497.	1/04/2013	30/06/2016	N		\$196,474.70
2011-12	University of Adelaide	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): A novel approach to predict metastatic potential of prostate cancer at diagnosis	1/03/2011	30/03/2014	N		\$650,905.20
2011-12	University of Adelaide	A combinatorial approach targeting androgen signalling for treatment of prostate cancer	12/03/2010	31/03/2012	N		\$321,028.95
2011-12	University of Adelaide	2011 - Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - Androgen receptor action in the prostate cancer microenvironment	20/03/2012	31/05/2015	N		\$316,571.20
2011-12	University of Adelaide	The role of CD123 in MDSA and AML	28/02/2011	13/03/2014	N		\$316,276.40
2011-12	University of Adelaide	2011 - Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - Is elevated N-cadherin expression a poor prognostic indicator in multiple myeloma patients	20/03/2012	17/03/2015	N		\$290,766.30
2019-20	University of Adelaide	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Novel co-extinction strategies for treatment of prostate cancer APPID: 1138766-Butler	16/04/2018	29/06/2021	N	N	\$596,409
2017-18	University of Melbourne	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2013	30/09/2019	N	N	\$599,381.00
2017-18	University of Melbourne	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/04/2014	31/03/2019	N	N	\$593,893.00

2017-18	University of Melbourne	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/03/2018	29/06/2021	N	N	\$589,082.00
2017-18	University of Melbourne	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	15/03/2016	14/06/2019	N	N	\$258,345.00
2017-18	University of Melbourne	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	3/05/2016	2/08/2019	N	N	\$299,822.00
2017-18	University of Melbourne	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/06/2015	31/08/2018	N	N	\$439,418.00
2017-18	University of Melbourne	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/06/2014	30/09/2018	N	N	\$498,012.00
2015-16	UNIVERSITY OF MELBOURNE	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2010: PERSONALISED BREAST CANCER RISK PREDICTION IN BRCA MUTATION CARRIERS:1007765	1/04/2011	30/09/2016	N		\$152,780.10
2015-16	UNIVERSITY OF MELBOURNE	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2012: SOLVING UNKNOWN PRIMARY CANCER - SUPER. APPL ID 1048193.	1/06/2013	30/09/2018	N		\$599,381.00
2015-16	UNIVERSITY OF MELBOURNE	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): IDENTIFICATION OF MEN WITH A GENETIC PREDISPOSITION TO PROSTATE CANCER: TARGETED SCREENING IN MEN AT HIGHER GENETIC RISK AND CONTROLS – THE IMPACT STUDY. APP1059423	1/05/2014	1/08/2017	N		\$292,151.00
2015-16	UNIVERSITY OF MELBOURNE	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): A RANDOMISED PHASE II TRIAL OF ADAPTIVE IMAGE GUIDED STANDARD OR DOSE ESCALATED RADIOTHERAPY IN THE TREATMENT OF TRANSITIONAL CELL CARCINOMA OF THE BLADDER (RAIDER-B). APP1063072	1/07/2014	30/09/2017	N		\$280,000.00
2015-16	UNIVERSITY OF MELBOURNE	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): MAXIMISING BENEFITS AND MINIMISING HARMS IN THE BREASTSCREEN PROGRAM: A POPULATION HEALTH ECONOMICS MODELLING APPROACH.APP1066771	1/04/2014	30/06/2017	N		\$593,893.00
2015-16	UNIVERSITY OF MELBOURNE	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): QUANTIFYING GENETIC RISK IN SARCOMA AND TRANSLATION INTO HEALTH OUTCOMES. APP1067094	21/03/2014	20/06/2017	N		\$597,793.00
2015-16	UNIVERSITY OF MELBOURNE	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): NOVEL THERAPIES TO TREAT BRAIN METASTATIC BREAST CANCER.APP1067045	1/05/2014	30/07/2017	N		\$398,447.00
2015-16	UNIVERSITY OF MELBOURNE	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): INVESTIGATION OF MOLECULAR IMAGING AND SERUM BIOMARKERS TO IDENTIFY LUNG INJURY AND ENABLE INDIVIDUALISED RADIATION THERAPY FOR LUNG CANCERS. APP ID: 1060919	1/04/2014	30/06/2017	N		\$498,012.00
2015-16	UNIVERSITY OF MELBOURNE	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): A RANDOMISED TRIAL OF STEREOTACTIC RADIOTHERAPY VERSUS CONVENTIONAL RADIOTHERAPY FOR STAGE I NON-SMALL CELL LUNG CANCER. APP ID: 1060822	1/06/2014	30/08/2017	N		\$320,000.00
2015-16	UNIVERSITY OF MELBOURNE	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): HIGH RISK GENES FOR CHILDHOOD CANCER: USING MASSIVELY PARALLEL SEQUENCING TO IDENTIFY CANCER SUSCEPTIBILITY. APP ID: 1070106	30/06/2014	30/09/2016	N		\$200,000.00
2015-16	UNIVERSITY OF MELBOURNE	2014 PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): INVESTIGATING THE SAFETY AND EFFICACY, QUALITY OF LIFE, COST-EFFICIENCY AND IMMUNE POTENTIAL OF HIGH PRECISION LUNG RADIOTHERAPY. APP. 1082399	1/06/2015	31/08/2018	N		\$439,418.00
2015-16	UNIVERSITY OF MELBOURNE	SUPPORTING PEOPLE WITH CANCER (SPWC) 2015- ENGAGE THE VIETNAMESE COMMUNITY TO DEVELOP CULTURALLY-SPECIFIC RESOURCES AND A SUPPORTING COMMUNITY ENGAGEMENT CAMPAIGN TO RAISE AWARENESS ABOUT CANCER SYMPTOMS AND PROMOTE EARLIER PRESENTATION TO HEALTHCARE IN THE VIETNAMESE COMMUNITY.	12/06/2015	30/06/2018	N		\$120,000.00
2015-16	UNIVERSITY OF MELBOURNE	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2015: TRANSLATING EVIDENCE INTO PRACTICE: OPTIMISING AND FACILITATING PREVENTION AND SCREENING IN WOMEN WITH A STRONG FAMILY HISTORY OF BREAST CANCER: ID1100868	15/03/2016	16/06/2019	N		\$258,345.00
2015-16	UNIVERSITY OF MELBOURNE	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2015: RESOLUTION OF THE MISSING HERITABILITY OF BREAST CANCER: ID1107870	3/05/2016	2/08/2019	N		\$299,822.00
2016-17	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Solving Unknown Primary cancer - SUPER. Appl ID 1048193.	1/06/2013	30/09/2018	N	NA	\$599,381.00

2016-17	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Identification of Men with a genetic predisposition to Prostate Cancer: Targeted screening in men at higher genetic risk and controls – The IMPACT study. App1059423	1/05/2014	31/03/2018	N	NA	\$292,151.00
2016-17	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Maximising benefits and minimising harms in the BreastScreen program: a population health economics modelling approach.App1066771	1/04/2014	30/06/2018	N	NA	\$593,893.00
2016-17	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Novel Therapies to Treat Brain Metastatic Breast Cancer.App1067045	1/05/2014	30/07/2017	N	NA	\$398,447.00
2016-17	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Investigation of molecular imaging and serum biomarkers to identify lung injury and enable individualised radiation therapy for lung cancers.App1060919	1/06/2014	30/09/2018	N	NA	\$498,012.00
2016-17	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): A randomised trial of stereotactic radiotherapy versus conventional radiotherapy for stage I non-small cell lung cancer. App ID: 1060822	1/06/2014	31/03/2018	N	NA	\$320,000.00
2016-17	University of Melbourne	2014 Priority Driven Collaborative Cancer Research Scheme (PdCCRS): Investigating the safety and efficacy, quality of life, cost-efficiency and immune potential of high precision lung radiotherapy. App. 1082399	1/06/2015	31/08/2018	N	NA	\$439,418.00
2016-17	University of Melbourne	SPWC - Engage the Vietnamese community to develop culturally-specific resources and a supporting community engagement campaign to raise awareness about cancer symptoms and promote earlier presentation to healthcare in the Vietnamese community.	12/06/2015	30/06/2018	N	NA	\$120,000.00
2016-17	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PdCCRS) 2015: Translating Evidence into Practice: Optimising and Facilitating Prevention and Screening in Women with a Strong Family History of Breast Cancer: ID1100868	15/03/2016	14/06/2019	N	NA	\$258,345.00
2016-17	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PdCCRS) 2015: Resolution of the missing heritability of breast cancer: ID1107870	3/05/2016	2/08/2019	N	NA	\$299,822.00
2014-15	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme 2011: Defining the hereditary contribution to ovarian cancer: The role of mismatch repair genes	23/02/2012	31/10/2015	N		\$614,090.40
2014-15	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme 2011: Determining Predictors of Sensitivity to Chk Inhibitors in Metastatic Melanoma.	14/03/2012	31/03/2016	N		\$651,585.00
2014-15	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme 2012: Solving Unknown Primary Cancer	24/01/2013	31/08/2016	N		\$599,381.00
2014-15	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme 2012: High Risk genes for Lobular Breast Cancer.	11/02/2013	31/05/2016	N		\$100,000.00
2014-15	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme: Identification of Men with a genetic predisposition to Prostate Cancer: Targeted screening in men at higher genetic risk and controls	21/03/2014	1/08/2017	N		\$292,151.00
2014-15	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme: A Randomised phase II trial of Adaptive Image guided standard or Dose Escalated Radiotherapy in the treatment of transitional cell carcinoma of the Bladder.	16/06/2014	30/09/2017	N		\$280,000.00
2014-15	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme: Maximising benefits and minimising harms in the BreastScreen program: a population health economics modelling approach.	5/03/2014	30/06/2017	N		\$593,893.00
2014-15	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme: Quantifying genetic risk in sarcoma and translation into health outcomes.	21/03/2014	20/06/2017	N		\$597,793.00
2014-15	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme: Novel Therapies to Treat Brain Metastatic Breast Cancer	28/03/2014	30/07/2017	N		\$398,447.00
2014-15	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme: Investigation of molecular imaging and serum biomarkers to identify lung injury and enable individualised radiation therapy for lung cancers.	16/06/2014	30/06/2017	N		\$498,012.00
2014-15	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme: A randomised trial of stereotactic radiotherapy versus conventional radiotherapy for stage I non-small cell lung cancer.	16/06/2014	30/08/2017	N		\$320,000.00
2014-15	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme: High risk genes for childhood cancer: using massively parallel sequencing to identify cancer susceptibility.	17/06/2014	30/09/2016	N		\$200,000.00
2014-15	University of Melbourne	2014 Priority Driven Collaborative Cancer Research Scheme: Investigating the safety and efficacy, quality of life, cost-efficiency and immune potential of high precision lung radiotherapy.	1/06/2015	31/08/2018	N		\$219,709.00

2014-15	University of Melbourne	Supporting People with Cancer - Engage the Vietnamese community to develop culturally-specific resources and a supporting community engagement campaign to raise awareness about cancer symptoms and promote earlier presentation to healthcare in the Vietnamese community.	12/06/2015	30/06/2018	N		\$120,000.00
2013-14	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: A randomised controlled trial evaluating a nurse-led survivorship care package (SurvivorCare) for bowel cancer survivors	21/05/2012	31/10/2014	N	N	\$206,250.00
2013-14	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Phase III randomised trial of post mastectomy chest wall irradiation in intermediate risk operable breast cancer	9/02/2011	31/08/2014	N	N	\$561,000.00
2013-14	University of Melbourne	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Genetic and environmental factors in invasive cervical cancer: a twin study	15/08/2013	14/05/2014	N	N	\$429,458.70
2013-14	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Sequencing the ovarian cancer genome: molecular determinants of tumour growth & treatment failure	30/06/2011	30/09/2014	N	N	\$660,000.00
2013-14	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Targeting dormancy in metastatic breast cancer	23/02/2012	28/05/2015	N	N	\$148,179.90
2013-14	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Defining the hereditary contribution to ovarian cancer: The role of mismatch repair genes	23/02/2012	28/05/2015	N	N	\$614,090.40
2013-14	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Determining Predictors of Sensitivity to Chk Inhibitors in Metastatic Melanoma	20/03/2012	13/06/2015	N	N	\$651,585.00
2013-14	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Solving Unknown Primary cancer - SUPER. Appl ID 1048193.	24/01/2013	31/08/2016	N	N	\$599,381.00
2013-14	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: High Risk genes for Lobular Breast Cancer. Appl ID 1047347.	11/02/2013	31/05/2016	N	N	\$100,000.00
2013-14	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Identification of Men with a genetic predisposition to Prostate Cancer: Targeted screening in men at higher genetic risk and controls – The IMPACT study. App1059423	21/03/2014	1/08/2017	N	N	\$292,151.00
2013-14	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): A Randomised phase II trial of Adaptive Image guided standard or Dose Escalated Radiotherapy in the treatment of transitional cell carcinoma of the Bladder (RAIDER-B). App1063072	16/06/2014	30/09/2017	N	N	\$280,000.00
2013-14	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Maximising benefits and minimising harms in the BreastScreen program: a population health economics modelling approach. App1066771	5/03/2014	30/06/2017	N	N	\$593,893.00
2013-14	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Quantifying genetic risk in sarcoma and translation into health outcomes. App1067094	21/03/2014	20/06/2017	N	N	\$597,793.00
2013-14	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Novel Therapies to Treat Brain Metastatic Breast Cancer. App1067045	28/03/2014	30/07/2017	N	N	\$398,447.00
2013-14	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Investigation of molecular imaging and serum biomarkers to identify lung injury and enable individualised radiation therapy for lung cancers. App1060919	16/06/2014	30/06/2017	N	N	\$498,012.00
2013-14	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): A randomised trial of stereotactic radiotherapy versus conventional radiotherapy for stage I non-small cell lung cancer. App1060822	16/06/2014	30/08/2017	N	N	\$320,000.00
2013-14	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Personalised breast cancer risk prediction in BRCA mutation carriers. Appl ID 1007765	23/05/2014	31/03/2015	N	N	\$152,780.10
2013-14	University of Melbourne	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): High risk genes for childhood cancer: using massively parallel sequencing to identify cancer susceptibility. App1070106	17/06/2014	30/09/2016	N	N	\$200,000.00
2013-14	University of Melbourne	2008 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Characterisation of the kConFab BRCA cohort for selected breast cancer susceptibility loci and effect on cancer risk: App ID 566791	16/06/2014	31/03/2015	N	N	\$527,107.90
2012-13	University of Melbourne	Support for Cancer Clinical Trials-Australasian Sarcoma Study Group (ASSG)	25/06/2010	31/08/2013	N		\$1,521,478.10
2012-13	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Sequencing the ovarian cancer genome: molecular determinants of tumour growth & treatment failure	30/06/2011	30/09/2014	N		\$660,000.00
2012-13	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Determining Predictors of Sensitivity to Chk Inhibitors in Metastatic Melanoma	20/03/2012	13/06/2015	N		\$651,585.00
2012-13	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Defining the hereditary contribution to ovarian cancer: The role of mismatch repair genes	23/02/2012	28/05/2015	N		\$614,090.40

2012-13	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Phase III randomised trial of post mastectomy chest wall irradiation in intermediate risk operable breast cancer	9/02/2011	31/08/2014	N		\$561,000.00
2012-13	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Identifying therapeutic targets by profiling DNA repair in lung cancer	9/02/2011	31/05/2014	N		\$552,776.40
2012-13	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Identification of Men with a genetic predisposition to Prostate Cancer: targeted screening in BRCA1/2 mutation carriers and controls - The Impact study	9/02/2011	31/05/2014	N		\$465,329.70
2012-13	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: A randomised trial of stereotactic vs conventional radiotherapy for inoperable early stage non-small cell lung cancer	30/01/2009	31/03/2014	N		\$286,000.00
2012-13	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: A randomised controlled trial evaluating a nurse-led survivorship care package (SurvivorCare) for bowel cancer survivors	14/04/2010	31/10/2014	N		\$206,250.00
2012-13	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Fulfilling the vision of youth-friendly cancer care: How well are we meeting the psychosocial needs of AYA patients?	9/02/2011	27/05/2014	N		\$164,776.70
2012-13	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Personalised breast cancer risk prediction in BRCA mutation carriers	9/02/2011	30/06/2014	N		\$152,780.10
2012-13	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Targeting dormancy in metastatic breast cancer	23/02/2012	28/05/2015	N		\$148,179.90
2012-13	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Solving Unknown Primary cancer - SUPER. Appl ID 1048193.	1/06/2013	31/08/2016	N		\$599,381.00
2012-13	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: High Risk genes for Lobular Breast Cancer. Appl ID 1047347.	1/03/2013	31/05/2016	N		\$100,000.00
2012-13	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: Novel MicroRNA regulators in the Breast Cancer EMT	1/03/2010	31/03/2014	N		\$256,019.00
2012-13	University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Genetic and environmental factors in invasive cervical cancer: a twin study	15/02/2011	14/05/2014	N		\$390,417.00
2011-12	University of Melbourne	Support for Cancer Clinical Trials	25/06/2010	30/06/2013	N		\$1,522,950.00
2011-12	University of Melbourne	Sequencing the ovarian cancer genome: molecular determinants of tumour growth & treatment failure	30/06/2011	30/06/2014	N		\$660,000.00
2011-12	University of Melbourne	2011 - Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - Determining Predictors of Sensitivity to Chk Inhibitors in Metastatic Melanoma	20/03/2012	13/03/2015	N		\$651,585.00
2011-12	University of Melbourne	2011 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - Defining the hereditary contribution to ovarian cancer: The role of mismatch repair genes	23/02/2012	28/02/2015	N		\$614,090.40
2011-12	University of Melbourne	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Phase III randomised trial of post mastectomy chest wall irradiation in intermediate risk operable breast cancer	9/02/2011	31/05/2014	N		\$561,000.00
2011-12	University of Melbourne	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Identifying therapeutic targets by profiling DNA repair in lung cancer	9/02/2011	27/02/2014	N		\$552,776.40
2011-12	University of Melbourne	Characterisation of the kConFab BRCA cohort for selected breast cancer susceptibility loci and effect on cancer risk	30/01/2009	31/01/2013	N		\$527,107.90
2011-12	University of Melbourne	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Identification of Men with a genetic predisposition to Prostate Cancer: targeted screening in BRCA1/2 mutation carriers and controls - The Impact study	9/02/2011	28/02/2014	N		\$465,329.70
2011-12	University of Melbourne	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Genetic and environmental factors in invasive cervical cancer: a twin study	9/02/2011	14/02/2013	N		\$429,458.70
2011-12	University of Melbourne	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Preventing breast cancer in BRCA1 and BRCA2 mutation carriers: kConFab Follow-up Project	29/01/2010	28/02/2013	N		\$327,731.25
2011-12	University of Melbourne	Methylation in ductal carcinoma in situ	30/01/2009	31/01/2013	N		\$294,398.69
2011-12	University of Melbourne	A randomised trial of stereotactic vs conventional radiotherapy for inoperable early stage non-small cell lung cancer	30/01/2009	31/12/2013	N		\$286,000.00
2011-12	University of Melbourne	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Novel MicroRNA regulators in the Breast Cancer EMT	29/01/2010	28/02/2013	N		\$281,620.90
2011-12	University of Melbourne	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Identification of BRCAx genes through targeted next generation sequencing	29/01/2010	28/02/2013	N		\$231,000.00
2011-12	University of Melbourne	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): A randomised controlled trial evaluating a nurse-led survivorship care package (SurvivorCare) for bowel cancer survivors	21/05/2012	12/04/2014	N		\$206,250.00
2011-12	University of Melbourne	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Fulfilling the vision of youth-friendly cancer care: How well are we meeting the psychosocial needs of AYA patients?	9/02/2011	27/02/2014	N		\$164,776.70

2011-12	University of Melbourne	2010 Priority Driven Collaborative Cancer Research Scheme (PdCCRS): Personalised breast cancer risk prediction in BRCA mutation carriers	9/02/2011	31/03/2014	N		\$152,780.10
2011-12	University of Melbourne	2011 Priority Driven Collaborative Cancer Research Scheme (PdCCRS) - Targeting dormancy in metastatic breast cancer	23/02/2012	28/02/2015	N		\$148,179.90
2011-12	University of Melbourne	Support for Cancer Clinical Trials	25/06/2010	30/06/2013	N		\$1,522,950.00
2018-19	University of Melbourne	Capacity building support to the Australasian Sarcoma Study Group (ASSG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,410,000.00
2018-19	University of Melbourne	Capacity building support to the Primary Care Collaborative Cancer Clinical Trials Group (PC4) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,500,000.00
2018-19	University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: SCORE: Shared care of Colorectal cancer survivors – A randomised controlled trial of hospital-based follow up versus shared hospital / general practice follow up for survivors of colorectal cancer (CRC) AppID: 1158397-JEFFORD	01/04/2019	30/06/2022	N	N	\$479,375.00
2019-20	University of Melbourne	Capacity building support to the Australia and New Zealand Sarcoma Association (ANZSA; formerly ASSG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,500,000
2019-20	University of Melbourne	Capacity building support to the Primary Care Collaborative Cancer Clinical Trials Group (PC4) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,500,000
2019-20	University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Integrative approaches to identifying the causes of familial breast cancer. APPID: 1188547-Campbell	27/04/2020	26/07/2023	N	N	\$547,825
2019-20	University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: The Preclinical Validation of Radio-labelled Girentuximab as a Theranostic Agent in Metastatic Colorectal Cancer. APPID: 1184859-Hollande	23/03/2020	23/06/2023	N	N	\$506,210
2019-20	University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: SCRIPT: an RCT of genomic-based stratified colorectal cancer screening in primary care. APPID: 1183338-Emery	30/06/2020	29/09/2023	N	N	\$551,184
2019-20	University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) international 2019: Genomic and epigenomic monitoring of residual disease using liquid biopsies. APPID: 663175-Dawson	01/01/2021	31/12/2023	N	N	\$670,500
2019-20	University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: SCORE: Shared care of Colorectal cancer survivors – A randomised controlled trial of hospital-based follow up versus shared hospital / general practice follow up for survivors of colorectal cancer (CRC) AppID: 1158397-JEFFORD	01/04/2019	30/06/2022	N	N	\$479,375
2019-20	University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Stereotactic Ablative Radiotherapy (SABR) as a New Precision Treatment Option in Kidney Cancer APPID: 1139464-Siva	30/03/2018	29/06/2021	N	N	\$589,082
2019-20	University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: Translating Evidence into Practice: Optimising and Facilitating Prevention and Screening in Women with a Strong Family History of Breast Cancer. APPID: 1100868-Phillips	15/03/2016	31/03/2020	N	N	\$258,345
2017-18	University of Melbourne Centre for Cancer Research	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	27/03/2017	30/06/2020	N	N	\$115,000.00
2016-17	University of Melbourne Centre for Cancer Research	Supporting people with cancer Grant initiative: PanSupport	27/03/2017	27/03/2017	N	NA	\$115,000.00
2016-17	University of Melbourne/Australasian Sarcoma Study Group	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2018	N	NA	\$2,299,998.00
2016-17	University of Melbourne/Primary Care Collaborative Cancer Clinical Trials Group	Support for Cancer Clinical Trials Program	1/07/2013	31/08/2018	N	NA	\$2,299,859.00
2017-18	University of New South Wales	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	29/03/2018	28/06/2021	N	N	\$592,694.00
2017-18	University of New South Wales	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/06/2018	31/08/2019	N	N	\$100,000.00
2017-18	University of New South Wales	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2018	29/09/2021	N	N	\$597,632.00
2017-18	University of New South Wales	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2017	29/09/2020	N	N	\$247,983.25
2017-18	University of New South Wales	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2017	29/09/2020	N	N	\$600,000.00
2017-18	University of New South Wales	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/05/2014	1/08/2018	N	N	\$457,353.00

2015-16	UNIVERSITY OF NEW SOUTH WALES	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): A MULTICENTRE PHASE II RANDOMISED CONTROLLED TRIAL OF A PARENT/CARER-TARGETED INTERVENTION TO IMPROVE QUALITY OF LIFE IN FAMILIES OF YOUNG CANCER SURVIVORS. APP1065428	1/05/2014	1/08/2017	N		\$457,353.00
2015-16	UNIVERSITY OF NEW SOUTH WALES	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): MRP4 AND MRP3 TRANSPORTERS: POTENTIAL NEW TARGETS IN OVARIAN CANCER. APP ID: 1067110	15/06/2014	14/09/2017	N		\$589,989.00
2016-17	University of New South Wales	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Reprogramming the Tumour Microenvironment with the use of Nanomedicines for the Treatment of Pancreatic Cancer: ID1126736	30/06/2017	29/09/2020	N	NA	\$247,983.25
2016-17	University of New South Wales	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Therapeutically targeting a solute carrier transporter in the stroma of pancreatic cancer. ID1126738.	30/06/2017	29/09/2020	N	NA	\$511,966.00
2016-17	University of New South Wales	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Improving outcomes for high risk ALL treated with new therapies and transplant. ID1128727.	30/06/2017	29/09/2020	N	NA	\$600,000.00
2016-17	University of New South Wales	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): A multicentre phase II randomised controlled trial of a parent/carer-targeted intervention to improve quality of life in families of young cancer survivors. App1065428	1/05/2014	1/08/2017	N	NA	\$457,353.00
2016-17	University of New South Wales	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): MRP4 and MRP3 transporters: potential new targets in ovarian cancer. App ID: 1067110	15/06/2014	14/09/2017	N	NA	\$589,989.00
2014-15	University of New South Wales	2013 Priority-driven Collaborative Cancer Research Scheme: A multicentre phase II randomised controlled trial of a parent/carer-targeted intervention to improve quality of life in families of young cancer survivors.	27/02/2014	1/08/2017	N		\$457,353.00
2014-15	University of New South Wales	2013 Priority-driven Collaborative Cancer Research Scheme: Multidrug resistance-associated protein 4 and Multidrug resistance-associated protein 3 transporters: potential new targets in ovarian cancer.	10/06/2014	14/09/2017	N		\$589,989.00
2013-14	University of New South Wales	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Mechanisms underpinning how brain cancer cells respond to drugs	20/03/2012	30/06/2015	N	N	\$534,793.00
2013-14	University of New South Wales	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Development of an optimised intervention for post-cancer fatigue	12/11/2013	30/09/2014	N	N	\$474,650.00
2013-14	University of New South Wales	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): A multicentre phase II randomised controlled trial of a parent/carer-targeted intervention to improve quality of life in families of young cancer survivors. App1065428	27/02/2014	1/08/2017	N	N	\$457,353.00
2013-14	University of New South Wales	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): MRP4 and MRP3 transporters: potential new targets in ovarian cancer. App1067110	10/06/2014	14/09/2017	N	N	\$589,989.00
2012-13	University of New South Wales	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: 'ReCaPTure LiFe': A phase 11 randomised trial of a psychological intervention to support adolescent and young adult cancer survivors	17/02/2012	13/06/2014	N		\$148,811.85
2012-13	University of New South Wales	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: Too much, too soon? The impact of treatment-focused genetic testing in patients newly diagnosed with breast cancer	16/02/2010	30/11/2013	N		\$217,998.00
2012-13	University of New South Wales	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Mechanisms underpinning how brain cancer cells respond to drugs	20/03/2012	31/06/2015	N		\$534,793.00
2011-12	University of New South Wales	The use and impact of cancer medicines in real world clinical practice: Evaluation in a cohort of elderly Australians	2/02/2009	31/12/2012	N		\$459,525.00
2011-12	University of New South Wales	2011 - Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 'ReCaPTure LiFe': A phase 11 randomised trial of a psychological intervention to support adolescent and young adult cancer survivors	17/02/2012	13/04/2014	N		\$148,811.85
2011-12	University of New South Wales	Development of an optimised intervention for post-cancer fatigue	15/06/2009	30/06/2012	N		\$474,650.00
2011-12	University of New South Wales	Development of an optimised intervention for post-cancer fatigue	15/06/2009	30/06/2012	N		\$474,650.00
2011-12	University of New South Wales	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Too much, too soon? The impact of treatment-focused genetic testing in patients newly diagnosed with breast cancer	9/02/2010	31/08/2013	N		\$217,998.00
2018-19	University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Decoding the Dark Matter of the High-Risk Paediatric Cancer Genome AppID: 1165556-COWLEY	07/05/2019	06/08/2022	N	N	\$377,048.00
2018-19	University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting Polo like kinase 1 as a novel therapeutic opportunity for Diffuse Intrinsic Pontine Gliomas AppID: 1165708-ZIEGLER	28/05/2019	27/08/2022	N	N	\$278,281.00

2018-19	University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting the NAD pathway as a new therapeutic strategy for high-risk leukaemia in children AppID: 1164865-HENDERSON	20/05/2019	19/08/2022	N	N	\$321,045.00
2018-19	University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS)2018: Therapeutic targeting of a novel self-renewal signalling in leukaemia stem cells AppID: 1165516-WANG	30/06/2019	29/09/2022	N	N	\$300,000.00
2019-20	University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Application of gene-silencing nanodrugs to inhibit medulloblastoma growth. APPID: 1184840-McCarroll	26/02/2020	25/05/2023	N	N	\$298,554
2019-20	University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Enhanced polyamine depletion as a novel therapy for aggressive childhood cancers. APPID: 1188234-Haber	01/01/2021	31/03/2024	N	N	\$347,705
2019-20	University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Functional precision medicine for aggressive childhood cancers. APPID: 1185313-Kavallaris	01/10/2020	30/12/2023	N	N	\$596,955
2019-20	University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Decoding the Dark Matter of the High-Risk Paediatric Cancer Genome AppID: 1165556-COWLEY	07/05/2019	06/08/2022	N	N	\$377,048
2019-20	University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting Polo like kinase 1 as a novel therapeutic opportunity for Diffuse Intrinsic Pontine Gliomas AppID: 1165708-ZIEGLER	28/05/2019	27/08/2022	N	N	\$278,281
2019-20	University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting the NAD pathway as a new therapeutic strategy for high-risk leukaemia in children AppID: 1164865-HENDERSON	20/05/2019	19/08/2022	N	N	\$321,045
2019-20	University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS)2018: Therapeutic targeting of a novel self-renewal signalling in leukaemia stem cells AppID: 1165516-WANG	30/06/2019	31/03/2023	N	N	\$300,000
2019-20	University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Microtubule deregulation in lung cancer and therapeutic strategies APPID: 1141485-Kavallaris	29/03/2018	28/06/2021	N	N	\$592,694
2019-20	University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: The contribution of rare alleles to non high grade serous ovarian cancer APPID: 1147276-Ramus	30/06/2018	29/08/2021	N	N	\$597,632
2012-13	University of Newcastle	Priority Driven Collaborative Cancer Research Scheme (PdCCRS) 2008: Blood cancer survivors and support persons: A national survey of rural/urban unmet needs and psychological disturbance	4/02/2009	31/08/2013	N		\$285,360.90
2011-12	University of Newcastle	Blood cancer survivors and support persons: A national survey of rural/urban unmet needs and psychological disturbance	4/02/2009	28/02/2012	N		\$285,360.90
2019-20	University of NSW	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Synthetic retinoid therapy for Diffuse Intrinsic Pontine Gliomas. APPID: 1126580-Ziegler	14/04/2017	13/07/2020	N	N	\$200,000
2019-20	University of NSW	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Improving outcomes for high risk ALL treated with new therapies and transplant. APPID: 1128727-Sutton	30/06/2017	29/09/2020	N	N	\$600,000
2017-18	University of Queensland	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2018	29/09/2021	N	N	\$400,000.00
2017-18	University of Queensland	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2018	29/09/2021	N	N	\$400,000.00
2017-18	University of Queensland	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/06/2016	31/08/2018	N	N	\$380,674.00
2017-18	University of Queensland	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/06/2015	31/08/2018	N	N	\$540,000.00
2015-16	UNIVERSITY OF QUEENSLAND	2014 PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PdCCRS): THE FEMME TRIAL. APP. 1078121	1/06/2015	31/08/2018	N		\$540,000.00
2015-16	UNIVERSITY OF QUEENSLAND	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PdCCRS) 2015: LONG-TERM FOLLOW-UP OF THE LAPAROSCOPIC APPROACH TO CARCINOMA OF THE ENDOMETRIUM (LACE) TRIAL – SURVIVAL OUTCOMES: ID1098905	1/06/2016	31/08/2018	N		\$380,674.00
2016-17	University of Queensland	2014 Priority Driven Collaborative Cancer Research Scheme (PdCCRS): The femMe trial. App. 1078121	1/06/2015	31/08/2018	N	NA	\$540,000.00
2016-17	University of Queensland	Priority Driven Collaborative Cancer Research Scheme (PdCCRS) 2015: Long-term follow-up of the Laparoscopic Approach to Carcinoma of the Endometrium (LACE) Trial – survival outcomes: ID1098905	1/06/2016	31/08/2018	N	NA	\$380,674.00

2014-15	University of Queensland	2014 Priority Driven Collaborative Cancer Research Scheme: The feMMe trial.	1/06/2015	31/08/2018	N		\$540,000.00
2013-14	University of Queensland	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Auto fluorescence imaging for early detection and surgical margin delineation of oral cancers and pre-cancers	28/02/2011	1/08/2014	N	N	\$558,131.20
2012-13	University of Queensland	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Auto fluorescence imaging for early detection and surgical margin delineation of oral cancers and pre-cancers	28/02/2011	1/08/2014	N		\$558,131.20
2012-13	University of Queensland	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: Post operative enteral nutrition in patients with advanced epithelial ovarian cancer	26/02/2010	31/05/2013	N		\$523,820.00
2011-12	University of Queensland	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): LACE - Laparoscopic approach to Carcinoma of the Endometrium. An International Multicentre Randomised Phase 3 Clinical Trial	27/01/2010	31/05/2013	N		\$643,775.00
2011-12	University of Queensland	Auto fluorescence imaging for early detection and surgical margin delineation of oral cancers and pre-cancers	28/02/2011	1/05/2014	N		\$558,131.20
2011-12	University of Queensland	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Post operative enteral nutrition in patients with advanced epithelial ovarian cancer	26/02/2010	31/05/2013	N		\$261,910.00
2018-19	University of Queensland	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Exploiting CDK4/6 inhibition to treat medulloblastoma AppID: 1165777-WAINWRIGHT	30/06/2019	29/09/2022	N	N	\$196,206.00
2019-20	University of Queensland	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Exploiting CDK4/6 inhibition to treat medulloblastoma AppID: 1165777-WAINWRIGHT	30/06/2019	29/09/2022	N	N	\$196,206
2019-20	University of Queensland	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Development of oxytocin receptor specific tracers for improved breast cancer management APPID: 1146504-Alewood	30/06/2018	29/08/2021	N	N	\$400,000
2019-20	University of Queensland	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Streamlining lung cancer diagnosis through genomic testing of cytology smears APPID: 1147067-Fielding	30/06/2018	29/08/2021	N	N	\$400,000
2017-18	University of South Australia	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/05/2016	30/07/2019	N	N	\$290,983.00
2015-16	UNIVERSITY OF SOUTH AUSTRALIA	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2015: TARGETING THE IL-3/IL-3 RECEPTOR AXIS TO PREVENT BREAST CANCER PROGRESSION: ID1105828	1/05/2015	30/07/2019	N		\$290,983.00
2016-17	University of South Australia	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2015: Targeting the IL-3/IL-3 receptor axis to prevent breast cancer progression: ID1105828	1/05/2015	30/07/2019	N	NA	\$290,983.00
2012-13	University of South Australia	Provision of Professional Research Epidemiological Services	1/04/2011	30/09/2013	N		\$603,981.35
2011-12	University of South Australia	Provision of Professional Research Epidemiological Services	1/04/2011	30/06/2013	N		\$473,786.64
2011-12	University of Southern Queensland	A randomised trial of a shorter radiation fractionation schedule for the treatment of localised prostate cancer (PROFIT - Prostate Fractionated Irradiation Trial)	12/02/2009	28/02/2012	N		\$487,850.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/06/2013	30/09/2019	N	N	\$252,583.48
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	19/03/2018	13/06/2021	N	N	\$296,601.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/05/2018	30/07/2021	N	N	\$583,371.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	19/03/2018	18/06/2021	N	N	\$492,411.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/04/2017	30/06/2020	N	N	\$213,459.53
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2017	29/09/2020	N	N	\$597,325.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/04/2017	30/06/2020	N	N	\$481,698.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	17/04/2017	16/07/2020	N	N	\$300,000.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2017	29/09/2020	N	N	\$148,857.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2016	29/09/2019	N	N	\$233,158.50
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/04/2016	30/06/2019	N	N	\$524,365.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/03/2016	28/05/2019	N	N	\$497,544.00

2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	15/04/2016	14/07/2019	N	N	\$600,000.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	18/04/2016	18/07/2019	N	N	\$598,099.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2016	29/09/2019	N	N	\$350,000.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	20/06/2015	20/09/2018	N	N	\$297,525.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2015	29/09/2018	N	N	\$458,459.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	28/02/2015	28/02/2019	N	N	\$441,385.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/05/2015	30/07/2018	N	N	\$335,963.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/05/2015	30/07/2018	N	N	\$600,000.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/06/2015	28/02/2019	N	N	\$193,800.00
2017-18	University of Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	17/02/2012	31/03/2020	N	N	\$200,000.00
2015-16	UNIVERSITY OF SYDNEY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2008: RANDOMISED MULTICENTRE PHASE III STUDY IN PATIENTS WITH LOCALLY ADVANCE ADENOCARCINOMA OF THE PANCREAS: GEMCITABINE WITH OR WITHOUT CHEMORADIO THERAPY AND WITH OR WITHOUT ERLOTINIB	31/01/2009	31/10/2016	N		\$284,900.00
2015-16	UNIVERSITY OF SYDNEY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2011: GIKGO BILOBA PRESERVES COGNITIVE FUNCTION IN WOMEN TREATED WITH ADJUVANT CHEMOTHERAPY FOR EARLY BREAST CANCER: A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED PHASE III TRIAL	17/02/2012	16/11/2016	N		\$220,000.00
2015-16	UNIVERSITY OF SYDNEY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2012: PETACC-6: PREOPERATIVE CHEMORADIO THERAPY AND POSTOPERATIVE CHEMOTHERAPY WITH CAPECITABINE AND OXALIPLATIN VS. CAPECITABINE ALONE IN LOCALLY ADVANCED RECTAL CANCER. APPL ID 1048035	4/03/2013	30/06/2017	N		\$123,331.00
2015-16	UNIVERSITY OF SYDNEY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2012: THE USE AND IMPACT OF HIGH COST TARGETED CANCER MEDICINES: THEORY AND REALITY. APPL ID 1050648	4/03/2013	31/03/2017	N		\$133,002.00
2015-16	UNIVERSITY OF SYDNEY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2012: ACCELERATING FIRST-LINE CHEMOTHERAPY TO IMPROVE CURE RATES FOR ADVANCED GERM CELL TUMOURS: AN AUSTRALIAN-LED, INTERNATIONAL RANDOMISED TRIAL. APPL ID 1041733	1/06/2013	31/10/2017	N		\$252,583.48
2015-16	UNIVERSITY OF SYDNEY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2012: ADDING MITOMYCIN C TO INTRAVESICAL BCG FOR HIGH-RISK, NON-MUSCLE-INVASIVE BLADDER CANCER: A RANDOMISED PHASE 3 TRIAL. APPL ID 1041651	1/06/2013	31/05/2017	N		\$457,143.17
2015-16	UNIVERSITY OF SYDNEY	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): HITTING THE TARGET: REAL-TIME PROSTATE CANCER RADIO THERAPY. APP1064731	1/06/2014	31/08/2017	N		\$171,854.00
2015-16	UNIVERSITY OF SYDNEY	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): ECHO TRIAL: EXERCISE DURING CHEMOTHERAPY FOR OVARIAN CANCER. APP1063509	1/04/2014	30/06/2017	N		\$300,000.00
2015-16	UNIVERSITY OF SYDNEY	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): ASCOLT: ASPIRIN FOR DUKES C AND HIGH RISK DUKES B COLORECTAL CANCERS. AN INTERNATIONAL, MULTI-CENTRE, DOUBLE BLIND, RANDOMISED TRIAL. APP1068044	1/04/2014	30/06/2017	N		\$276,811.50
2015-16	UNIVERSITY OF SYDNEY	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): PHASE 2 STUDY OF AROMATASE INHIBITORS IN WOMEN WITH POTENTIALLY HORMONE SENSITIVE RECURRENT/METASTATIC GYNAECOLOGICAL NEOPLASMS: PARAGON. APP1063014	1/06/2014	30/08/2017	N		\$546,676.00
2015-16	UNIVERSITY OF SYDNEY	2013 PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): REZOLVE: A PHASE II STUDY TO EVALUATE THE SAFETY AND POTENTIAL PALLIATIVE BENEFIT OF INTRAPERITONEAL BEVACIZUMAB IN PATIENTS WITH SYMPTOMATIC ASCITES DUE TO ADVANCED CHEMOTHERAPY RESISTANT GYNAECOLOGICAL CANCERS. APP1067589	9/06/2014	8/09/2017	N		\$119,280.00
2015-16	UNIVERSITY OF SYDNEY	2014 PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): PHASE III TRIAL OF CONCURRENT & ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY IN NON-1P/19Q DELETED ANAPLASTIC GLIOMA. APP.1078665	28/02/2015	27/05/2018	N		\$190,213.00

2015-16	UNIVERSITY OF SYDNEY	2014 PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS):PAIN FREE TRUS B: A PLACEBO-CONTROLLED, RANDOMISED TRIAL OF METHOXYFLURANE TO REDUCE THE DISCOMFORT OF PROSTATE BIOPSY. APP.1079794	20/06/2015	20/09/2018	N		\$297,525.00
2015-16	UNIVERSITY OF SYDNEY	2014 PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): REDUCING THORACIC IMAGING DOSE AND IMPROVING IMAGE QUALITY IN RADIO THERAPY TREATMENTS. APP.1084566	30/06/2015	29/09/2018	N		\$458,459.00
2015-16	UNIVERSITY OF SYDNEY	2014 PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS):REAL-TIME SIX DEGREE OF FREEDOM TUMOUR MOTION MANAGEMENT IN CANCER RADIO THERAPY. APP.1085360	28/02/2015	28/02/2019	N		\$441,385.00
2015-16	UNIVERSITY OF SYDNEY	2014 PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): ANZMTG 01.07 WHOLE BRAIN RADIO THERAPY (WBRT) FOLLOWING LOCAL TREATMENT OF INTRACRANIAL METASTASES OF MELANOMA – A RANDOMISED PHASE III TRIAL. APP. 1084046	1/05/2015	30/07/2018	N		\$335,963.00
2015-16	UNIVERSITY OF SYDNEY	2014 PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): ANZMTG 01.12 RADICAL – RADIO THERAPY (RT) OR IMIQUIMOD (IMIQ) IN COMPLEX LENTIGO MALIGNA (LM). APP. 1083221	1/05/2015	30/07/2018	N		\$600,000.00
2015-16	UNIVERSITY OF SYDNEY	2014 PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS): SPARK: STEREOTACTIC PROSTATE ADAPTIVE RADIO THERAPY UTILISING KILOVOLTAGE INTRAFRACTION MONITORING. APP. 1081534	1/06/2015	30/08/2018	N		\$387,599.00
2015-16	UNIVERSITY OF SYDNEY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2015: DEVELOPING A PATIENT-REPORTED SYMPTOM INDEX FOR NON-MUSCLE INVASIVE BLADDER CANCER: ID1103036	30/06/2016	30/09/2019	N		\$233,159.00
2015-16	UNIVERSITY OF SYDNEY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2015: PHASE II RANDOMISED PLACEBO-CONTROLLED, DOUBLE BLIND, MULTISITE STUDY OF ACETAZOLAMIDE VERSUS PLACEBO FOR MANAGEMENT OF CEREBRAL OEDEMA IN RECURRENT AND/OR PROGRESSIVE HGG REQUIRING TREATMENT WITH DEXAMETHASONE – THE ACED TRIAL: ID1098932	1/04/2016	30/06/2019	N		\$524,365.00
2015-16	UNIVERSITY OF SYDNEY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2015: ADJUVANT CHEMOTHERAPY WITH GEMCITABINE AND CISPLATIN COMPARED TO OBSERVATION AFTER CURATIVE INTENT RESECTION OF CHOLANGIOCARCINOMA AND MUSCLE INVASIVE GALLBLADDER CARCINOMA (ACTICCA-1 TRIAL): ID1100306	1/03/2016	28/05/2019	N		\$497,544.00
2015-16	UNIVERSITY OF SYDNEY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2015: ICON9: A PHASE 3 RANDOMISED TRIAL OF CEDIRANIB AND OLAPARIB MAINTENANCE IN PATIENTS WITH RELAPSED PLATINUM SENSITIVE OVARIAN CANCER: ID1100619	6/04/2016	6/07/2019	N		\$513,981.00
2015-16	UNIVERSITY OF SYDNEY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2015: THE PEARL TRIAL: PALLIATIVE CARE EARLY IN ADVANCED LUNG CANCERS: ID1101882	18/04/2016	18/07/2019	N		\$500,000.00
2015-16	UNIVERSITY OF SYDNEY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2015: COUNTING THE COST OF CURING CHILDHOOD ALL BY TRANSPLANTATION: ID1102140	30/06/2016	29/09/2019	N		\$350,000.00
2015-16	UNIVERSITY OF SYDNEY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2011: CONQUER FEAR: A RANDOMISED TRIAL OF AN INTERVENTION TO REDUCE FEAR OF CANCER RECURRENCE ID 1022584	1/03/2012	30/11/2016	N		\$165,567.34
2015-16	UNIVERSITY OF SYDNEY	PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PDCCRS) 2012: A PHASE II STUDY TO EVALUATE THE SAFETY AND POTENTIAL BENEFIT OF INTRAPERITONEAL (IP) BEVACIZUMAB TO CONTROL SYMPTOMATIC MALIGNANT ASCITES IN PATIENTS WITH CHEMOTHERAPY RESISTANT OVARIAN CANCERS: REZOLVE (ANZGOG-1101) ID 1050134	28/06/2013	29/09/2016	N		\$277,958.00
2016-17	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: ASCOLT: Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers. An International, Multi-centre, Double Blind, Randomised Trial: ID1122632	1/04/2017	30/06/2020	N	NA	\$213,459.53
2016-17	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: High Precision Radiotherapy: Dual Cardiac and Respiratory Motion Management: ID1123068	30/06/2017	29/09/2020	N	NA	\$597,325.00
2016-17	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Computed tomography (CT) and positron emission tomography (PET)/CT surveillance imaging in asymptomatic Stage III melanoma patients - a prospective cohort study of clinical benefit and economic implications: ID1129568	1/04/2017	30/06/2020	N	NA	\$481,698.00

2016-17	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Phase II clinical trial of the PARP inhibitor, olaparib, in HR- deficient advanced breast and ovarian cancer in women without inherited BRCA1 or BRCA2 mutations: ID1128740	17/04/2017	16/07/2020	N	NA	\$300,000.00
2016-17	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: The SPAR Trial: a randomised placebo-controlled phase 2 trial of simvastatin with preoperative chemoradiation for rectal cancer. ID1125958.	30/06/2017	29/09/2020	N	NA	\$148,857.00
2016-17	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Evaluation of a psychological and educational intervention for fear of cancer recurrence; A cluster randomised controlled trial; App1022584	1/03/2012	30/09/2017	N	NA	\$182,124.07
2016-17	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Ginkgo biloba preserves cognitive function in women treated with adjuvant chemotherapy for early breast cancer: a double-blind, placebo-controlled, randomised phase III trial; App1029819	17/02/2012	31/03/2018	N	NA	\$220,000.00
2016-17	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Adding mitomycin C to intravesical BCG for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial. Appl ID 1041651	1/06/2013	30/06/2018	N	NA	\$457,143.17
2016-17	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours: An Australian-Led, International Randomised Trial. Appl ID 1041733	1/06/2013	31/10/2017	N	NA	\$252,583.48
2016-17	University of Sydney	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Hitting the Target: Real-Time Prostate Cancer Radiotherapy. App1064731	1/06/2014	31/08/2017	N	NA	\$343,706.00
2016-17	University of Sydney	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Phase 2 study of aromatase inhibitors in women with potentially hormone sensitive recurrent/metastatic gynaecological neoplasms: PARAGON. App1063014	1/06/2014	30/08/2017	N	NA	\$546,676.00
2016-17	University of Sydney	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): REZOLVE: A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers. App1067589	9/06/2014	8/09/2017	N	NA	\$119,280.00
2016-17	University of Sydney	2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Phase III trial of Concurrent & Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. App.1078665	28/02/2015	27/05/2018	N	NA	\$190,213.00
2016-17	University of Sydney	2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS):Pain Free TRUS B: A placebo-controlled, randomised trial of methoxyflurane to reduce the discomfort of prostate biopsy. App.1079794	20/06/2015	20/09/2018	N	NA	\$297,525.00
2016-17	University of Sydney	2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Reducing Thoracic Imaging Dose and Improving Image Quality in Radiotherapy Treatments. App.1084566	30/06/2015	29/09/2018	N	NA	\$458,459.00
2016-17	University of Sydney	2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS):Real-time Six Degree of Freedom Tumour Motion Management in Cancer Radiotherapy. App.1085360	28/02/2015	28/02/2019	N	NA	\$441,385.00
2016-17	University of Sydney	2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): ANZMTG 01.07 Whole Brain Radiotherapy (WBRT) following local treatment of intracranial metastases of melanoma – a randomised phase III trial. App. 1084046	1/05/2015	30/07/2018	N	NA	\$335,963.00
2016-17	University of Sydney	2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): ANZMTG 01.12 RADICAL – Radiotherapy (RT) or Imiquimod (ImiQ) in Complex lentigo maligna (LM). App. 1083221	1/05/2015	30/07/2018	N	NA	\$600,000.00
2016-17	University of Sydney	2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): SPARK: STEREOTACTIC PROSTATE ADAPTIVE RADIOTHERAPY UTILISING KILOVOLTAGE INTRAFRACTION MONITORING. App. 1081534	1/06/2015	30/08/2018	N	NA	\$387,599.00
2016-17	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2015: Developing a Patient-Reported Symptom Index for Non-muscle Invasive Bladder Cancer: ID1103036	30/06/2016	29/08/2019	N	NA	\$233,158.50
2016-17	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2015: Phase II randomised placebo-controlled, double blind, multisite study of acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive HGG requiring treatment with dexamethasone – The ACED trial: ID1098932	1/04/2016	30/06/2019	N	NA	\$524,365.00

2016-17	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2015: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 Trial): ID1100306	1/03/2016	28/05/2019	N	NA	\$497,544.00
2016-17	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2015: ICON9: A phase 3 randomised trial of cediranib and olaparib maintenance in patients with relapsed platinum sensitive ovarian cancer: ID1100619	15/04/2016	15/07/2019	N	NA	\$600,000.00
2016-17	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2015: The PEARL trial: Palliative care Early in Advanced Lung cancers: ID1101882	18/04/2016	18/07/2019	N	NA	\$598,099.00
2016-17	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2015: Counting the Cost of Curing Childhood ALL by Transplantation: ID1102140	30/06/2016	29/09/2019	N	NA	\$350,000.00
2014-15	University of Sydney	Priority Driven Collaborative Cancer Research Scheme 2008: Randomised Multicentre Phase III Study in patients with locally advanced adenocarcinoma of the pancreas: gemcitabine with or without chemoradiotherapy and with or without erlotinib	31/01/2009	31/10/2016	N		\$284,900.00
2014-15	University of Sydney	Priority Driven Collaborative Cancer Research Scheme 2010: Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - a randomised phase III trial	1/03/2011	28/05/2016	N		\$650,111.00
2014-15	University of Sydney	Priority Driven Collaborative Cancer Research Scheme 2011: PORTEC-3 - The role of adjuvant chemotherapy in high-risk endometrial cancer	9/01/2012	31/03/2016	N		\$330,965.80
2014-15	University of Sydney	Priority Driven Collaborative Cancer Research Scheme 2011: Evaluation of web-based tool for estimating and explaining prognosis in advanced cancer	9/01/2012	30/04/2016	N		\$139,933.75
2014-15	University of Sydney	Priority Driven Collaborative Cancer Research Scheme 2011: Ginkgo biloba preserves cognitive function in women treated with adjuvant chemotherapy for early breast cancer: a double-blind, placebo-controlled, randomised phase III trial	17/02/2012	16/11/2016	N		\$220,000.00
2014-15	University of Sydney	Priority Driven Collaborative Cancer Research Scheme 2012: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer.	1/03/2013	3/06/2016	N		\$123,331.00
2014-15	University of Sydney	Priority Driven Collaborative Cancer Research Scheme 2012: The Use and Impact of High Cost Targeted Cancer Medicines: Theory and Reality.	1/03/2013	31/03/2017	N		\$133,002.00
2014-15	University of Sydney	Priority Driven Collaborative Cancer Research Scheme 2012: Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours: An Australian-Led, International Randomised Trial.	1/03/2013	31/10/2017	N		\$252,583.48
2014-15	University of Sydney	Priority Driven Collaborative Cancer Research Scheme 2012: The cost-effectiveness of adjuvant whole brain radiotherapy for melanoma brain metastases: a trial-based and modelled economic evaluation.	1/03/2013	3/06/2016	N		\$184,475.00
2014-15	University of Sydney	Priority Driven Collaborative Cancer Research Scheme 2012: Adding mitomycin C to intravesical BCG for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial.	1/03/2013	31/08/2016	N		\$457,143.17
2014-15	University of Sydney	Priority Driven Collaborative Cancer Research Scheme 2012: An international multi-stage randomised phase III trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy for women with newly diagnosed epithelial ovarian cancer.	1/03/2013	3/06/2016	N		\$257,241.00
2014-15	University of Sydney	2013 Priority-driven Collaborative Cancer Research Scheme: Hitting the Target: Real-Time Prostate Cancer Radiotherapy.	16/06/2014	31/08/2017	N		\$171,854.00
2014-15	University of Sydney	2013 Priority-driven Collaborative Cancer Research Scheme: ECHO trial: Exercise during Chemotherapy for Ovarian cancer.	21/03/2014	30/06/2017	N		\$300,000.00
2014-15	University of Sydney	2013 Priority-driven Collaborative Cancer Research Scheme: Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers. An International, Multi-centre, Double Blind, Randomised Trial.	28/03/2014	30/06/2017	N		\$276,811.50
2014-15	University of Sydney	2013 Priority-driven Collaborative Cancer Research Scheme: Phase 2 study of aromatase inhibitors in women with potentially hormone sensitive recurrent/metastatic gynaecological neoplasms	20/05/2014	30/08/2017	N		\$546,676.00
2014-15	University of Sydney	2013 Priority-driven Collaborative Cancer Research Scheme: REZOLVE: A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers.	9/06/2014	8/09/2017	N		\$119,280.00
2014-15	University of Sydney	2014 Priority Driven Collaborative Cancer Research Scheme : Phase III trial of Concurrent & Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma.	17/02/2015	27/05/2018	N		\$190,213.00
2014-15	University of Sydney	2014 Priority Driven Collaborative Cancer Research Scheme: Pain Free TRUS B: A placebo-controlled, randomised trial of methoxyflurane to reduce the discomfort of prostate biopsy.	17/02/2015	20/09/2018	N		\$297,525.00

2014-15	University of Sydney	2014 Priority Driven Collaborative Cancer Research Scheme : Reducing Thoracic Imaging Dose and Improving Image Quality in Radiotherapy Treatments.	17/02/2015	29/09/2018	N		\$458,459.00
2014-15	University of Sydney	2014 Priority Driven Collaborative Cancer Research Scheme: Real-time Six Degree of Freedom Tumour Motion Management in Cancer Radiotherapy.	17/02/2015	27/05/2018	N		\$441,385.00
2014-15	University of Sydney	2014 Priority Driven Collaborative Cancer Research Scheme : Australia and New Zealand Melanoma Trials Group 01.07 Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial.	13/04/2015	30/07/2018	N		\$335,963.00
2014-15	University of Sydney	2014 Priority Driven Collaborative Cancer Research Scheme : Australia and New Zealand Melanoma Trials Group 01.12 – Radiotherapy or Imiquimod in Complex lentigo maligna	13/04/2015	30/07/2018	N		\$600,000.00
2014-15	University of Sydney	2014 Priority Driven Collaborative Cancer Research Scheme: Stereostatic Prostate Adaptive Radiotherapy utilising Kilovoltage Intrafraction Monitoring	29/04/2015	30/08/2018	N		\$193,800.00
2014-15	University of Sydney	2014 Priority Driven Collaborative Cancer Research Scheme: Stereotactic Prostate Adaptive Radiotherapy utilising Kilovoltage Intrafraction Monitoring.	29/04/2015	30/08/2018	N		\$193,799.00
2013-14	University of Sydney	Technical Services of a Genomic Cancer Clinical Trial Initiative (GCCTI) to develop mutation-specific cancer clinical trials protocols	25/06/2013	1/08/2016	N	N	\$1,350,000.00
2013-14	University of Sydney	Cancer Learning Website Redevelopment	11/12/2013	31/12/2014	N	N	\$200,000.00
2013-14	University of Sydney	Technical services of a quality-of-life office to the 13 trials groups supported under the Support for Cancer Clinical Trials program	25/06/2013	1/08/2016	N	N	\$750,000.00
2013-14	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: Timing of surgery and adjuvant chemotherapy for hepatic metastases from colorectal cancer	21/05/2012	31/10/2014	N	N	\$660,000.00
2013-14	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: The role of adjuvant chemotherapy in high-risk endometrial cancer	9/01/2012	30/04/2015	N	N	\$330,965.80
2013-14	University of Sydney	2011 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Phas III trial of Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q non deleted anaplastic glioma. The CATNON Intergroup Trial: App ID: 1026842	9/01/2012	30/04/2015	N	N	\$217,896.25
2013-14	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Evaluation of web-based tool for estimating and explaining prognosis in advanced cancer	9/01/2012	30/04/2015	N	N	\$139,933.75
2013-14	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Evaluation of a psychological and educational intervention for fear of cancer recurrence; A cluster randomised controlled trial	9/01/2012	28/05/2015	N	N	\$182,124.07
2013-14	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: PETACC-6: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer. Appl ID 1048035	1/03/2013	3/06/2016	N	N	\$123,331.00
2013-14	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: The Use and Impact of High Cost Targeted Cancer Medicines: Theory and Reality. Appl ID 1050648	1/03/2013	3/06/2016	N	N	\$133,002.00
2013-14	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours: An Australian-Led, International Randomised Trial. Appl ID 1041733	1/03/2013	31/08/2016	N	N	\$252,583.48
2013-14	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: The cost-effectiveness of adjuvant whole brain radiotherapy for melanoma brain metastases: a trial-based and modelled economic evaluation. Appl ID 1046923	1/03/2013	3/06/2016	N	N	\$184,475.00
2013-14	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Adding mitomycin C to intravesical BCG for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial. Appl ID 1041651	1/03/2013	31/08/2016	N	N	\$457,143.17
2013-14	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: ICON8: An international multi-stage randomised phase III trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy for women with newly diagnosed epithelial ovarian cancer. Appl ID 1044344	1/03/2013	3/06/2016	N	N	\$257,241.00
2013-14	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Gikgo biloba preserves cognitive function in women treated with adjuvant chemotherapy for early breast cancer: a double-blind, placebo-controlled, randomised phase III trial	13/09/2013	16/11/2016	N	N	\$220,000.00
2013-14	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: The use of RNAi to identify new therapeutic targets for malignant mesothelioma	21/02/2012	16/02/2015	N	N	\$407,523.10

2013-14	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Randomised Multicentre Phase III Study in patients with locally advanced adenocarcinoma of the pancreas: gemcitabine with or without chemoradiotherapy and with or without erlotinib	7/05/2012	31/03/2015	N	N	\$284,900.00
2013-14	University of Sydney	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Hitting the Target: Real-Time Prostate Cancer Radiotherapy. App1064731	16/06/2014	31/08/2017	N	N	\$171,854.00
2013-14	University of Sydney	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): ECHO trial: Exercise during Chemotherapy for Ovarian cancer. App1063509	21/03/2014	30/06/2017	N	N	\$300,000.00
2013-14	University of Sydney	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): ASCOLT: Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers. An International, Multicentre, Double Blind, Randomised Trial.App1068044	28/03/2014	30/06/2017	N	N	\$276,811.50
2013-14	University of Sydney	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): REZOLVE: A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers. App1067589	10/06/2014	8/09/2017	N	N	\$119,280.00
2013-14	University of Sydney	2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Phase 2 study of aromatase inhibitors in women with potentially hormone sensitive recurrent/metastatic gynaecological neoplasms: PARAGON. App1063014	20/05/2014	30/08/2017	N	N	\$546,676.00
2012-13	University of Sydney	To maintain the existing Cancer Learning and National Nursing Cancer Education Project (EdCan) websites, and to participate in scoping activities during the 2012/13 financial year regarding redevelopment and migration of sites across to a new Cancer Learning website.	21/11/2012	30/06/2013	N		\$211,578.00
2012-13	University of Sydney	Technical services of a quality-of-life office to the 13 trials groups supported under the Support for Cancer Clinical Trials program	25/06/2013	1/08/2016	N		\$750,000.00
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: The use of RNAi to identify new therapeutic targets for malignant mesothelioma	21/02/2012	16/05/2015	N		\$407,523.00
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Gikgo biloba preserves cognitive function in women treated with adjuvant chemotherapy for early breast cancer: a double-blind, placebo-controlled, randomised phase III trial	21/02/2012	16/05/2015	N		\$220,000.00
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Evaluation of web-based tool for estimating and explaining prognosis in advanced cancer	9/01/2012	31/04/2015	N		\$139,933.75
2012-13	University of Sydney	Support for Cancer Clinical Trials-Australasian Gastro-Intestinal Trials Group	25/06/2010	30/06/2013	N		\$1,503,716.10
2012-13	University of Sydney	Support for Cancer Clinical Trials-Australia New Zealand Gynaecological Oncology Group	25/06/2010	30/06/2013	N		\$1,531,004.40
2012-13	University of Sydney	Support for Cancer Clinical Trials - Australia and New Zealand Melanoma Trials Group (ANZMTG)	25/06/2010	31/08/2013	N		\$1,497,860.73
2012-13	University of Sydney	Support for Cancer Clinical Trials-Australia and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)	25/06/2010	31/08/2013	N		\$1,526,711.20
2012-13	University of Sydney	Support for Cancer Clinical Trials - Australasian Lung Cancer Trials Group (ALTG) and The Australian Lung Foundation	25/06/2010	31/08/2013	N		\$1,522,588.20
2012-13	University of Sydney	Support for Cancer Clinical Trials-Cooperative Trials Group for Neuro-Oncology (COGNO)	25/06/2010	31/08/2013	N		\$1,235,865.70
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: Timing of surgery and adjuvant chemotherapy for hepatic metastases from colorectal cancer	26/02/2010	31/10/2014	N		\$660,000.00
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: NITRO - A randomised, phase 3 trial of adding nitroglycerin to first line chemotherapy for advanced non - small cell lung cancer	1/03/2011	31/05/2014	N		\$656,421.70
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - a randomised phase III trial	1/03/2011	31/05/2014	N		\$650,111.00
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: Randomised trial of consumer-led familial cancer risk tool & GP triage on risk-appropriate colorectal cancer screening	26/02/2010	31/03/2014	N		\$611,875.00
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: The role of adjuvant chemotherapy in high-risk endometrial cancer	9/01/2012	31/04/2015	N		\$330,965.80
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: SCOT: A study of adjuvant chemotherapy in colorectal cancer	5/02/2009	31/03/2014	N		\$329,752.50
2012-13	University of Sydney	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): START Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favourable Risk Prostate Cancer	1/03/2011	28/02/2014	N		\$329,320.20

2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Randomised Multicentre Phase III Study in patients with locally advanced adenocarcinoma of the pancreas: gemcitabine with or without chemoradiotherapy and with or without erlotinib	4/02/2009	31/03/2015	N		\$284,900.00
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: A randomised, placebo-controlled trial of concurrent cediranib [AZD2171] with platinum - based chemotherapy & maintenance cediranib in women with platinum sensitive relapsed ovarian cancer: ICON 6	1/03/2011	30/06/2013	N		\$270,597.80
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Phase III trial of Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q non deleted anaplastic glioma. The CATNON Intergroup Trial	9/01/2012	31/04/2015	N		\$217,896.25
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Evaluation of a psychological and educational intervention for fear of cancer recurrence; A cluster randomised controlled trial	9/01/2012	28/05/2015	N		\$182,124.07
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: PETACC-6: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer. Appl ID 1048035	4/03/2013	3/06/2016	N		\$123,331.00
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: The Use and Impact of High Cost Targeted Cancer Medicines: Theory and Reality. Appl ID 1050648	4/03/2013	3/06/2016	N		\$133,002.00
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours: An Australian-Led, International Randomised Trial. Appl ID 1041733	1/06/2013	31/08/2016	N		\$252,583.48
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: The cost-effectiveness of adjuvant whole brain radiotherapy for melanoma brain metastases: a trial-based and modelled economic evaluation. Appl ID 1046923	4/03/2013	3/06/2016	N		\$184,475.00
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Adding mitomycin C to intravesical BCG for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial. Appl ID 1041651	1/06/2013	31/08/2016	N		\$457,143.17
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: A Phase II study to evaluate the safety and potential benefit of intraperitoneal (IP) bevacizumab to control symptomatic malignant ascites in patients with chemotherapy resistant ovarian cancers: REZOLVE (ANZGOG-1101). Appl ID 1050134	28/06/2013	29/09/2013	N		\$277,958.00
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Preferences for adjuvant chemotherapy in early non-small-cell lung cancer: what makes it worthwhile?	31/01/2009	31/03/2014	N		\$287,425.00
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Randomised phase III study of preop-chemoradiotherapy versus preop-chemotherapy for resectable gastric cancer	31/01/2009	30/04/2015	N		\$541,183.33
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: The use and impact of cancer medicines in real world clinical practice: Evaluation in a cohort of elderly Australians	31/01/2009	31/03/2014	N		\$417,750.00
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: RNA Loading of Tumour Associated Antigens and the Activation of Blood Dendritic Cells for Prostate Cancer Immunotherapy	31/01/2009	30/06/2015	N		\$297,450.00
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: Genomic determinants of chemosensitivity in ovarian cancer	1/03/2010	31/08/2013	N		\$549,750.00
2012-13	University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012 :ICON8: An international multi-stage randomised phase III trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy for women with newly diagnosed epithelial ovarian cancer	4/03/2013	3/06/2016	N		\$257,241.00
2011-12	University of Sydney	Undertake two systematic reviews of the evidence for Cancer suffering / spiritual issues and Cancer wellness	3/05/2012	30/06/2012	N		\$118,320.00
2011-12	University of Sydney	Cancer Clinical Trials Development Unit	25/06/2010	31/08/2013	N		\$690,590.27
2011-12	University of Sydney	2011 - Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - The use of RNAi to identify new therapeutic targets for malignant mesothelioma	21/02/2012	16/02/2015	N		\$411,650.80
2011-12	University of Sydney	2011 - Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - Ginkgo biloba preserves cognitive function in women treated with adjuvant chemotherapy for early breast cancer: a double-blind, placebo-controlled, randomised phase III trial	21/02/2012	16/02/2015	N		\$220,000.00

2011-12	University of Sydney	2011 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - Evaluation of web-based tool for estimating and explaining prognosis in advanced cancer	9/01/2012	31/01/2015	N		\$139,933.75
2011-12	University of Sydney	Support for Cancer Clinical Trials	25/06/2010	30/06/2013	N		\$1,541,030.40
2011-12	University of Sydney	Support for Cancer Clinical Trials	25/06/2010	30/06/2013	N		\$1,540,997.52
2011-12	University of Sydney	Support for Cancer Clinical Trials	25/06/2010	30/06/2013	N		\$1,534,589.43
2011-12	University of Sydney	Support for Cancer Clinical Trials	25/06/2010	31/08/2013	N		\$1,534,308.60
2011-12	University of Sydney	Support for Cancer Clinical Trials	25/06/2010	31/08/2013	N		\$1,523,481.30
2011-12	University of Sydney	Support for Clinical Trials: Cooperative Trials Group for Neuro-Oncology (COGNO)	25/06/2010	31/08/2013	N		\$1,242,144.20
2011-12	University of Sydney	NHMRC Cancer Clinical Trials Development Unit	25/06/2010	31/05/2012	N		\$856,179.88
2011-12	University of Sydney	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Timing of surgery and adjuvant chemotherapy for hepatic metastases from colorectal cancer	21/05/2012	31/07/2014	N		\$660,000.00
2011-12	University of Sydney	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): NITRO - A randomised, phase 3 trial of adding nitroglycerin to first line chemotherapy for advanced non - small cell lung cancer	1/03/2011	28/02/2014	N		\$656,421.70
2011-12	University of Sydney	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - a randomised phase III trial	1/03/2011	28/02/2014	N		\$650,111.00
2011-12	University of Sydney	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Randomised trial of consumer-led familial cancer risk tool & GP triage on risk-appropriate colorectal cancer screening	24/02/2010	31/12/2013	N		\$611,875.00
2011-12	University of Sydney	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Genomic determinants of chemosensitivity in ovarian cancer	26/02/2010	28/02/2013	N		\$604,725.00
2011-12	University of Sydney	Randomised phase III study of preop-chemoradiotherapy versus preop-chemotherapy for resectable gastric	5/02/2009	31/01/2013	N		\$595,301.66
2011-12	University of Sydney	Incidence and risk factors for lymphoedema secondary to breast cancer: a prospective cohort study	4/02/2009	31/01/2013	N		\$581,916.25
2011-12	University of Sydney	Priority-driven Collaborative Cancer Research Scheme-Clinical correlates of lymphoedema	1/02/2012	31/01/2013	N		\$467,995.00
2011-12	University of Sydney	2011 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - The role of adjuvant chemotherapy in high-risk endometrial cancer	9/01/2012	31/01/2015	N		\$330,965.80
2011-12	University of Sydney	Psychological morbidity, unmet needs, quality of life and patterns of care in migrant cancer patients: The first year	5/02/2009	30/06/2012	N		\$330,000.00
2011-12	University of Sydney	SCOT: A study of adjuvant chemotherapy in colorectal cancer	5/02/2009	31/12/2013	N		\$329,752.50
2011-12	University of Sydney	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): START Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favourable Risk Prostate Cancer	1/03/2011	28/02/2014	N		\$329,320.20
2011-12	University of Sydney	Preferences for adjuvant chemotherapy in early non-small-cell lung cancer: what makes it worthwhile?	4/02/2009	31/03/2013	N		\$316,167.50
2011-12	University of Sydney	Maintain and develop the Cancer Learning site to June 2012	24/01/2011	30/05/2012	N		\$299,337.50
2011-12	University of Sydney	Randomised Multicentre Phase III Study in patients with locally advanced adenocarcinoma of the pancreas: gemcitabine with or without chemoradiotherapy and with or without erlotinib	4/02/2009	31/12/2014	N		\$284,900.00
2011-12	University of Sydney	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): A randomised, placebo-controlled trial of concurrent cediranib [AZD2171] with platinum - based chemotherapy & maintenance cediranib in women with platinum sensitive relapsed ovarian cancer: ICON 6	1/03/2011	28/03/2013	N		\$270,597.80
2011-12	University of Sydney	2009 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Phase 2 study of aromatase inhibitors in women with potentially hormone sensitive recurrent/metastatic gynaecological neoplasms: PARAGON	21/01/2011	31/05/2013	N		\$242,481.80
2011-12	University of Sydney	2011 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - Phase III trial of Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q non deleted anaplastic glioma. The CATNON Intergroup Trial	9/01/2012	31/01/2015	N		\$217,896.25
2011-12	University of Sydney	Quality of life outcomes and cost effectiveness of pelvic exenteration for people with advanced rectal cancer	4/02/2009	31/12/2012	N		\$211,777.50
2011-12	University of Sydney	2011 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - Evaluation of a psychological and educational intervention for fear of cancer recurrence; A cluster randomised controlled trial	9/01/2012	28/02/2015	N		\$182,124.07
2011-12	University of Sydney	Support for Cancer Clinical Trials	25/06/2010	31/08/2011	N		\$1,627,835.03
2011-12	University of Sydney	Development of a 5 year cancer professional development strategic development plan	27/04/2011	28/10/2011	N		\$101,090.00
2011-12	University of Sydney	Priority Driven Collaborative Cancer Research Scheme - Prevention of osteoporosis after breast cancer treatment	3/11/2011	30/04/2012	N		\$230,422.50

2018-19	University of Sydney	Capacity building support to the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,410,000.00
2018-19	University of Sydney	Capacity building support to the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,410,000.00
2018-19	University of Sydney	Capacity building support to the Cooperative Trials Group for Neuro-Oncology (COGNO) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,410,000.00
2018-19	University of Sydney	Capacity building support to the Psycho-oncology Co-operative Research Group (PoCoG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,477,995.00
2018-19	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Personalised targeted therapy for adolescent and young adult medulloblastoma patients AppID: 1165910-HOVEY	30/06/2019	29/09/2022	N	N	\$167,168.50
2018-19	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: P3BEP Trial: Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours: An Australian-Led, International Randomised Trial. AppID: 1159837-GRIMISON	30/06/2019	29/09/2022	N	N	\$600,000.00
2018-19	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: The ECHO trial: Exercise during Chemotherapy for Ovarian cancer AppID: 1158566-HAYES	06/05/2019	05/08/2022	N	N	\$597,443.00
2018-19	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Improving tumour targeting and delineation in lung cancer radiotherapy AppID: 1161748-O'Brien	30/06/2019	29/09/2022	N	N	\$600,000.00
2018-19	University of Sydney	2019 Supporting People with Cancer Round 11	30/05/2019	30/05/2022	N	N	\$120,000.00
2018-19	University of Sydney	Capacity building support to the Australian Gastro-intestinal Trials Group (AGITG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,500,000.00
2018-19	University of Sydney	Capacity building support to the Australasian Lung Cancer Trials Group (ALTG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,500,000.00
2018-19	University of Sydney	Capacity building support to the Melanoma and Skin cancer Trials (formerly ANZMTG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	01/07/2018	01/09/2021	N	N	\$1,500,000.00
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: ASCOLT: ASpirin for Dukes C and high risk B COLorecTal cancer. An International, Multi-centre, Double Blind, Randomised Trial. APPID: 1182824-Segelov	13/05/2020	12/08/2023	N	N	\$465,000
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Remove the Mask: Reducing Anxiety and Distress for Head and Neck Cancer Radiotherapy Patients. APPID: 1180776-Keall	30/06/2020	29/09/2023	N	N	\$568,445
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Immuno-metabolic biomarkers to predict treatment response in metastatic prostate cancer. APPID: 1188642-Horvath	01/01/2021	31/03/2024	N	N	\$600,000
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Life and Health After Childhood Cancer: a national data linkage cohort study. APPID: 1187545-Nassar	01/06/2020	31/08/2023	N	N	\$569,900
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: The Liver Ablative Radiotherapy with KIM (LARK) Clinical Trial APPID:1143778-Keall	01/05/2018	30/07/2021	N	N	\$583,371
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Molecular drivers of malignancy and response to targeted treatment in chemotherapy-resistant low-grade serous ovarian cancer APPID: 1142697-de Fazio	19/03/2018	18/06/2021	N	N	\$492,411
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma: the CODEL trial. APPID: 1130584-Hovey	30/06/2017	29/09/2020	N	N	\$221,534
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: High Precision Radiotherapy: Dual Cardiac and Respiratory Motion Management. APPID: 1123068-O'Brien	30/06/2017	29/09/2020	N	N	\$597,326
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Phase II clinical trial of the PARP inhibitor, olaparib, in HR- deficient advanced breast and ovarian cancer in women without inherited BRCA1 or BRCA2 mutations. APPID: 1128740-Sjoquist	17/04/2017	16/07/2020	N	N	\$300,000

2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: The SPAR Trial: a randomised placebo-controlled phase 2 trial of simvastatin with preoperative chemoradiation for rectal cancer. APPID: 1125958-Ackland	30/06/2017	29/09/2020	N	N	\$148,857
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: The PEARL trial: Palliative care Early in Advanced Lung cancers. APPID: 1101882-Mileshkin	18/04/2016	30/09/2021	N	N	\$598,099
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: ICON9: A phase 3 randomised trial of cediranib and olaparib maintenance in patients with relapsed platinum sensitive ovarian cancer. APPID: 1100619-Mileshkin	15/04/2016	31/03/2022	N	N	\$600,000
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: Phase II randomised placebo-controlled, double blind, multisite study of acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive HGG requiring treatment with dexamethasone – The ACED trial. APPID: 1098932-Agar	01/04/2016	30/03/2022	N	N	\$524,365
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: Developing a Patient-Reported Symptom Index for Non-muscle Invasive Bladder Cancer. APPID: 1103036-Patel	30/06/2016	30/09/2021	N	N	\$233,159
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 Trial). APPID: 1100306-Shannon	01/03/2016	30/12/2020	N	N	\$497,544
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: Counting the Cost of Curing Childhood ALL by Transplantation. APPID: 1102140-Shaw	30/06/2016	30/09/2020	N	N	\$350,000
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2014: ANZMTG 01.12 RADICAL – RAdiotherapy (RT) or Imiquimod (ImiQ) in Complex lentigo mALigna (LM). APPID: 1083221-Guitera	01/05/2015	30/09/2020	N	N	\$600,000
2019-20	University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2014: ANZMTG 01.07 Whole Brain Radiotherapy (WBRT) following local treatment of intracranial metastases of melanoma – a randomised phase III trial. APPID: 1084046-Fogarty	01/05/2015	30/09/2020	N	N	\$335,963
2012-13	University of Sydney (School of Psychology)	Chair in Cancer Quality of Life	20/06/2011	31/08/2013	N		\$651,833.78
2011-12	University of Sydney (School of Psychology)	Psycho-oncology Co-operative Research Group, University of Sydney, NSW 2006	20/06/2011	31/08/2013	N		\$651,833.79
2017-18	University of Technology Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	30/06/2017	29/09/2020	N	N	\$342,483.00
2017-18	University of Technology Sydney	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/04/2017	30/06/2020	N	N	\$599,820.00
2016-17	University of Technology Sydney	Priority Driven Collaborative Cancer Research Scheme (PdCCRS) 2016: A phase III wait-listed RCT of a novel targeted inter-professional clinical education intervention to improve cancer patients' reported pain outcomes. ID1127011	30/06/2017	29/09/2020	N	NA	\$342,483.00
2016-17	University of Technology Sydney	Priority Driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Randomised double blind placebo controlled phase III trial of oral melatonin for the prevention of delirium in hospitalised advanced cancer patients: ID1127727	1/04/2017	30/06/2020	N	NA	\$599,820.00
2013-14	University of Technology Sydney	Technical services of health-economics and pharmaco-economics to the 13 trials groups supported under the Support for Cancer Clinical Trials program	25/06/2013	1/08/2016	N	N	\$898,896.00
2012-13	University of Technology Sydney	Provision of Health Economic & Pharmacoeconomic services for the multi-site collaborative national cancer clinical trials group	1/12/2010	31/08/2013	N		\$1,208,470.00
2012-13	University of Technology Sydney	Technical services of health-economics and pharmaco-economics to the 13 trials groups supported under the Support for Cancer Clinical Trials program	25/06/2013	1/08/2016	N		\$898,896.00
2011-12	University of Technology Sydney	Provision of Health Economic & Pharmacoeconomic services for the multi-site collaborative national cancer clinical trials group	1/12/2010	30/06/2013	N		\$1,208,469.98
2019-20	University of Technology Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: A phase III wait-listed RCT of a novel targeted inter-professional clinical education intervention to improve cancer patients' reported pain outcomes. APPID: 1127011-Phillips	30/06/2017	29/09/2020	N	N	\$342,483
2017-18	University of Western Australia	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	8/03/2018	7/06/2021	N	N	\$592,636.00
2017-18	University of Western Australia	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/05/2018	31/07/2021	N	N	\$530,428.00
2017-18	University of Western Australia	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	26/06/2017	25/09/2019	N	N	\$242,789.00
2015-16	UNIVERSITY OF WESTERN AUSTRALIA	2014 PRIORITY DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME (PdCCRS): MAMMOGRAPHIC DENSITY AS A PREDICTOR OF BREAST CANCER RISK AND MORTALITY IN WESTERN AUSTRALIAN ABORIGINAL WOMEN. APP. 1085750	11/05/2015	31/03/2017	N		\$137,651.00

2016-17	University of Western Australia	2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Mammographic density as a predictor of breast cancer risk and mortality in Western Australian Aboriginal women. App. 1085750	4/05/2015	31/03/2018	N	NA	\$137,651.00
2016-17	University of Western Australia	Priority Driven Collaborative CEGF-Receptor Antagonist in Mesothelioma (FRAME) Study: A Phase II Clinical Trial: ID1121215	26/06/2017	25/09/2017	N	NA	\$242,789.00
2014-15	University of Western Australia	2014 Priority Driven Collaborative Cancer Research Scheme: Mammographic density as a predictor of breast cancer risk and mortality in Western Australian Aboriginal women.	11/05/2015	31/03/2017	N		\$137,651.00
2013-14	University of Western Australia	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Endocrine therapies for early breast cancer: targets the National Health Priority Area of Cancer Control, specifically focussing on breast cancer treatment in Australian women.	7/02/2011	31/07/2014	N	N	\$171,048.90
2012-13	University of Western Australia	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Endocrine therapies for early breast cancer: targets the National Health Priority Area of Cancer Control, specifically focussing on breast cancer treatment in Australian women.	7/02/2011	31/07/2014	N		\$171,048.90
2012-13	University of Western Australia	Support for Cancer Clinical Trials-Primary Care Collaborative Cancer Clinical Trials Group (PC4TG)	22/06/2010	31/08/2013	N		\$1,480,792.20
2011-12	University of Western Australia	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Endocrine therapies for early breast cancer: targets the National Health Priority Area of Cancer Control, specifically focussing on breast cancer treatment in Australian women.	7/02/2011	30/04/2014	N		\$171,048.90
2011-12	University of Western Australia	Support for Cancer Clinical Trials	22/06/2010	30/06/2013	N		\$1,506,347.70
2018-19	University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Mixed radiotherapy fractionation: modulating tumour microenvironment to stimulate and enhance immunotherapy AppID: 1163065-EBERT	01/05/2019	30/07/2022	N	N	\$597,521.00
2019-20	University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Intraoperative immunotherapy to prevent relapse in soft tissue sarcoma. APPID: 1184331-Lesterhuis	01/04/2020	30/06/2022	N	N	\$197,525
2019-20	University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Mixed radiotherapy fractionation: modulating tumour microenvironment to stimulate and enhance immunotherapy AppID: 1163065-EBERT	01/05/2019	30/07/2022	N	N	\$597,521
2019-20	University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Measuring breast density in younger women to inform primary prevention and early detection of breast cancer AppID: 1147677-Stone	08/03/2018	07/06/2021	N	N	\$592,636
2019-20	University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Sensitising medulloblastoma to conventional treatment using kinase inhibitors AppID: 1147153-Gottardo	01/05/2018	31/07/2021	N	N	\$530,428
2014-15	University of Wollongong	Priority Driven Collaborative Cancer Research Scheme 2011: Quantifying the impact of imaging choice for breast cancer radiotherapy.	21/02/2012	31/10/2015	N		\$143,585.20
2013-14	University of Wollongong	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Quantifying the impact of imaging choice for breast cancer radiotherapy	21/02/2012	1/06/2015	N	N	\$143,585.20
2012-13	University of Wollongong	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Quantifying the impact of imaging choice for breast cancer radiotherapy	21/02/2012	1/06/2015	N		\$143,585.20
2011-12	University of Wollongong	2011 - Priority Driven Collaborative Cancer Research Scheme (PDCCRS) -Quantifying the impact of imaging choice for breast cancer radiotherapy	21/02/2012	1/03/2015	N		\$143,585.20
2011-12	Victorian Department of Human Services	The continuation of Cancer Service Networks National Demonstration Program (CanNET) in Victoria	7/06/2010	30/06/2012	N		\$810,152.00
2012-13	WA Cancer & Palliative Care Network	To develop best methodologies for complementing existing population based data with data on stage and treatment	5/03/2010	30/06/2013	N		\$927,795.00
2013-14	WA Cancer and Palliative Care Network (the State of Western Australia acting through Minister for Health)	Lung cancer service delivery to demonstrate best practice approaches to lung cancer treatment and care.	30/06/2014	30/06/2015	N	N	\$125,000.00
2018-19	Walter & Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting BCL-2 in estrogen receptor positive breast cancer AppID: 1165878-LINDEMAN	29/04/2019	28/07/2022	N	N	\$599,562.00
2019-20	Walter & Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting BCL-2 in estrogen receptor positive breast cancer AppID: 1165878-LINDEMAN	29/04/2019	28/07/2022	N	N	\$599,562
2019-20	Walter & Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting multidrug resistance protein 1 (MDR1) enhances the efficacy of Smac-mimetic-based therapy in Acute Myeloid Leukaemia AppID: 1162023-BRUMATTI	01/06/2019	31/08/2022	N	N	\$361,023

2019-20	Walter & Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Designing Chimeric Antigen Receptor T cells for Diffuse Intrinsic Pontine Glioma AppID: 1164657-JENKINS	06/05/2019	05/08/2022	N	N	\$592,388
2011-12	Walter and Eliza Hall Institute	Role of the GATA-3 transcription factor as a tumour suppressor and potential therapeutic target in breast	20/02/2009	28/02/2012	N		\$326,803.95
2017-18	Walter and Eliza Hall Institute of Medical Research	Support for Cancer Clinical Trials Program. Capacity building support to develop cancer clinical trial protocols	1/04/2017	30/06/2020	N	N	\$594,254.00
2016-17	Walter and Eliza Hall Institute of Medical Research	Priority Driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Development of a Clinico-Molecular Colon Cancer Nomogram for personalisation of adjuvant chemotherapy in the Australian population: ID1120882	1/04/2017	30/06/2020	N	NA	\$594,524.00
2018-19	Walter and Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting multidrug resistance protein 1 (MDR1) enhances the efficacy of Smac-mimetic-based therapy in Acute Myeloid Leukaemia AppID: 1162023-BRUMATTI	01/06/2019	31/08/2022	N	N	\$361,023.00
2018-19	Walter and Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Designing Chimeric Antigen Receptor T cells for Diffuse Intrinsic Pontine Glioma AppID: 1164657-JENKINS	06/05/2019	05/08/2022	N	N	\$592,388.00
2011-12	Walter Turnbull	Internal Audit Services	24/01/2008	31/12/2011	N		\$165,000.00
2011-12	Western Australian Department of Health	The continuation of Cancer Service Networks National Demonstration Program (CanNET) in Western Australia	10/02/2010	30/06/2012	N		\$225,525.00
2012-13	Western Australian Department of Health (known as Metropolitan Health Service)	To develop best methodologies for complementing existing population based data with data on stage and treatment	5/03/2010	30/06/2013	N		\$731,090.00
2011-12	Western Australian Department of Health (known as Metropolitan Health Service)	To develop best methodologies for complementing existing population based data with data on stage and treatment	20/04/2011	30/06/2013	N		\$843,450.00
2013-14	Westmead Breast Cancer Institute (Western Sydney Local Health District)	Procurement of evaluation data: Shared follow-up care for women with early breast cancer 2013-2015	28/06/2013	15/09/2015	N	N	\$140,000.00
2012-13	ZEST Health Strategies	Models of care in Australia for the management of people diagnosed with lung cancer	1/06/2011	28/06/2013	N		\$398,101.00
2011-12	ZEST Health Strategies	Models of care in Australia for the management of people diagnosed with lung cancer	1/06/2011	30/06/2013	N		\$393,469.00